of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 15 Oct 2008 VOL 149 ISS 16
FILE LAST UPDATED: 14 Oct 2008 (20081014/ED)

Caplus now includes complete International Patent Classification (IPC)
reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/legal/infopolicy.html

```
=> s l5
L8          20 L5

=> s l8 not (2008/so or 2007/so or 2006/so or 2005/so)
        657090 2008/SO
        967291 2007/SO
        945741 2006/SO
        884922 2005/SO
L9          19 L8 NOT (2008/SO OR 2007/SO OR 2006/SO OR 2005/SO)

=> d his

     (FILE 'HOME' ENTERED AT 10:15:37 ON 15 OCT 2008)

     FILE 'REGISTRY' ENTERED AT 10:15:43 ON 15 OCT 2008
L1              STRUCTURE UPLOADED
L2           50 S L1
L3          961 S L1 SSS FUL
L4        75421 S 5-6-7/SZ
L5          446 S L3 AND L4
L6          302 S L5 AND CAPLUS/LC
L7          144 S L5 NOT L6

     FILE 'CAPLUS' ENTERED AT 10:18:18 ON 15 OCT 2008
L8           20 S L5
L9           19 S L8 NOT (2008/SO OR 2007/SO OR 2006/SO OR 2005/SO)

=> d l1
L1 HAS NO ANSWERS
L1              STR
```




```
G1 C,N
```

L9 ANSWER 1 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:174325 CAPLUS
DOCUMENT NUMBER: 146:251874
TITLE: Preparation of tricyclic β-secretase inhibitors for the treatment of Alzheimer's disease
INVENTOR(S): Nantermet, Philippe G.
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 32pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007019078	A2	20070215	WO 2006-US29342	20060728
WO 2007019078	A3	20070712		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: US 2005-705228P P 20050803
OTHER SOURCE(S): MARPAT 146:251874
GI



I

AB Title compds. [I; X = oxadiazolylene, oxazolylene, imidazolylene, thiazolylene, isoxazolylene, aminopyrimidinylene, furylene; A = H, (substituted) alkyl, alkenyl; Q = (substituted) alkylene; R1 = (substituted) aryl, heteroaryl, alkyl; R2 = OH, amino; R3, R4 = alkyl, alkenyl, halo, alkoxy, amino, cyano, OH; m, n = 0-2; p = 1, 2; Y1Y2 = NR5SO2, NR5CO; R5 = H, alkyl, alkenyl, alkynyl, cyloalkyl, aryl, heteroaryl, aralkyl, heteroarylalkyl, arylcycloalkyl, heteroarylcycloalkyl; Y3Y4Y5 = NCR8:CR9; R8 = H, alkyl, cycloalkyl; R9 = H, alkyl, cycloalkyl, aryl, heteroaryl, aralkyl, heteroarylalkyl, etc.], were prepared Thus, (2R)-2-[5-(7-ethyl-1-methyl-2,2-dioxido-3,4-dihydro-1H-

1,2,5-thiadiazepino[3,4,5-hi]indol-9-yl)-1,3,4-oxadiazol-2-yl]-1-phenylpropan-2-amine [preparation from Me 7-ethyl-1-methyl-3,4-dihydro-1H-1,2,5-thiadiazepino[3,4,5-hi]indole-9-carboxylate 2,2-dioxide, α-methyl-D-phenylalanine, and tert-Bu carbazate given] inhibited β-secretase with an IC50 of between 1 nM and 100 μM.

IT 925455-50-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of tricyclic β-secretase inhibitors for the treatment of Alzheimer's disease)

RN 925455-50-1 CAPLUS

CN 1,3,4-Oxadiazole-2-methanamine, 5-(7-ethyl-3,4-dihydro-1-methyl-2,2-dioxido-1H-pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepin-9-yl)-α-methyl-α-(phenylmethyl)-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



IT 790254-40-9P 790254-64-7P 925455-51-2P
925455-52-3P 925455-53-4P 925455-54-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of tricyclic β-secretase inhibitors for the treatment of Alzheimer's disease)

RN 790254-40-9 CAPLUS

CN 1H-Pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxylic acid, 7-ethyl-3,4-dihydro-1-methyl-, methyl ester, 2,2-dioxide (CA INDEX NAME)



RN 790254-64-7 CAPLUS
CN 1H-Pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxylic acid, 7-ethyl-3,4-dihydro-1-methyl-, 2,2-dioxide (CA INDEX NAME)



RN 925455-51-2 CAPLUS
CN 1H-Pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxylic acid, 7-ethyl-3,4-dihydro-1-methyl-, 2-[(1,1-dimethylethoxy)carbonyl]hydrazide, 2,2-dioxide (CA INDEX NAME)



RN 925455-52-3 CAPLUS
CN 1H-Pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxylic acid, 7-ethyl-3,4-dihydro-1-methyl-, hydrazide, 2,2-dioxide (CA INDEX NAME)



RN 925455-53-4 CAPLUS

CN 1H-Pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxylic acid, 7-ethyl-3,4-dihydro-1-methyl-, 2-[2-[[(1,1-dimethylethoxy)carbonyl]amino]-2-methyl-1-oxo-3-phenylpropyl]hydrazide, 2,2-dioxide (CA INDEX NAME)

Absolute stereochemistry.



RN 925455-54-5 CAPLUS

CN Carbamic acid, N-[(1R)-1-[5-(7-ethyl-3,4-dihydro-1-methyl-2,2-dioxido-1H-pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepin-9-yl)-1,3,4-oxadiazol-2-yl]-1-methyl-2-phenylethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



L9 ANSWER 2 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:365268 CAPLUS
DOCUMENT NUMBER: 144:412550
TITLE: Tricyclic indole derivatives for use in the treatment of Alzheimer's disease
INVENTOR(S): Demont, Emmanuel Hubert; Redshaw, Sally; Walter, Daryl Simon
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 35 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006040148	A1	20060420	WO 2005-EP11001	20051011

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: GB 2004-22755 A 20041013
OTHER SOURCE(S): CASREACT 144:412550; MARPAT 144:412550
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The present invention relates to novel ketone compds. of formula I [R1 = H or C1-3 alkyl; R2 = C1-3 alkyl, C2-4 alkenyl, C2-4 alkynyl, etc.; m = 0-4; n = 0-2; A-B = -NR5SO2-; R5 = H, C1-6 alkyl, C3-6 alkenyl, etc.; -W- = -CH2-, -(CH2)2-, -(CH2)3-, etc.; X-Y-Z = -NCR8=CR9-; R8 = H, C1-6 alkyl or C3-10 cycloalkyl; R9 = H, C1-6 alkyl, C1-6 alkoxy, etc.; R3 = C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, etc.; R4 = H, C1-10 alkyl, C3-10 alkenyl, etc.] having Asp2 (β-secretase, BACE1 or Memapsin-2) inhibitory activity, processes for their preparation, to compns. containing them and to their use in the treatment of diseases characterized by elevated β-amyloid levels or β-amyloid deposits, particularly Alzheimer's disease. Thus, to a solution of 1,1-dimethylethyl ((3S)-3-{[(7-ethyl-1-methyl-2,2-dioxido-3,4-dihydro-1H-[1,2,5]thiadiazepino[3,4,5-hi]indol-9-yl)carbonyl]amino}-2-oxo-4-phenylbutyl)tetrahydro-2H-pyran-4-ylcarbamate (II) in dioxane was added 4-methylbenzenesulfonic acid hydrate and the resulting mixture was stirred at rt for 16 h. The mixture was partitioned between Et acetate and a saturated aqueous NaHCO3 solution The phases were separated and the organic phase was was washed,

dried and concentrated and the residue was purified by Mass Directed Autopreparation to give 7-ethyl-1-methyl-N-[(1S)-2-oxo-1-(phenylmethyl)-3-(tetrahydro-2H-pyran-4-ylamino)propyl]-3,4-dihydro-1H-[1,2,5]thiadiazepino[3,4,5-hi]indole-9-carboxamide 2,2-dioxide (III) in 35% yield. The exemplified compds. were tested in the Asp-2 inhibitory assay and the Cathepsin D inhibitory assay and exhibited inhibition < 10 μM in the Asp-2 inhibitory assay and > 10 fold selectivity for Asp2 over CatD.

IT 883726-66-7P 883726-67-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(tricyclic indole derivs. for use in the treatment of diseases characterized by elevated β-amyloid levels or β-amyloid deposits, particularly Alzheimer's disease)

RN 883726-66-7 CAPLUS
CN 1H-Pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxamide, 7-ethyl-3,4-dihydro-1-methyl-N-[(1S)-2-oxo-1-(phenylmethyl)-3-[(tetrahydro-2H-pyran-4-yl)amino]propyl]-, 2,2-dioxide (CA INDEX NAME)

Absolute stereochemistry.



RN 883726-67-8 CAPLUS
CN 1H-Pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxamide, 7-ethyl-3,4-dihydro-N-[(1S)-3-[[(3-methoxyphenyl)methyl]amino]-2-oxo-1-(phenylmethyl)propyl]-1-methyl-, 2,2-dioxide (CA INDEX NAME)

Absolute stereochemistry.



IT 790252-03-8P 790252-31-2P 790254-39-6P
790254-40-9P 790254-64-7P 883726-62-3P
883726-63-4P 883726-64-5P 883726-65-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(tricyclic indole derivs. for use in the treatment of diseases characterized by elevated β-amyloid levels or β-amyloid deposits, particularly Alzheimer's disease)

RN 790252-03-8 CAPLUS
CN 1H-Pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxamide, 7-ethyl-3,4-dihydro-N-[(1S,2R)-2-hydroxy-3-[[(3-methoxyphenyl)methyl]amino]-1-(phenylmethyl)propyl]-1-methyl-, 2,2-dioxide (CA INDEX NAME)

Absolute stereochemistry.



RN 790252-31-2 CAPLUS
CN 1H-Pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxamide, 7-ethyl-3,4-dihydro-N-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[(tetrahydro-2H-pyran-4-yl)amino]propyl]-1-methyl-, 2,2-dioxide (CA INDEX NAME)

Absolute stereochemistry.



RN 790254-39-6 CAPLUS
CN 1H-Pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxylic acid, 7-ethyl-3,4-dihydro-, methyl ester, 2,2-dioxide (CA INDEX NAME)



RN 790254-40-9 CAPLUS
CN 1H-Pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxylic acid, 7-ethyl-3,4-dihydro-1-methyl-, methyl ester, 2,2-dioxide (CA INDEX NAME)



RN 790254-64-7 CAPLUS
CN 1H-Pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxylic acid, 7-ethyl-3,4-dihydro-1-methyl-, 2,2-dioxide (CA INDEX NAME)



RN 883726-62-3 CAPLUS
CN Carbamic acid, [(2R,3S)-3-[[(7-ethyl-3,4-dihydro-1-methyl-2,2-dioxido-1H-pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepin-9-yl)carbonyl]amino]-2-hydroxy-4-phenylbutyl](tetrahydro-2H-pyran-4-yl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 883726-63-4 CAPLUS
CN Carbamic acid, [(2R,3S)-3-[[(7-ethyl-3,4-dihydro-1-methyl-2,2-dioxido-1H-pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepin-9-yl)carbonyl]amino]-2-hydroxy-4-phenylbutyl][(3-methoxyphenyl)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 883726-64-5 CAPLUS
CN Carbamic acid, [(3S)-3-[[(7-ethyl-3,4-dihydro-1-methyl-2,2-dioxido-1H-pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepin-9-yl)carbonyl]amino]-2-oxo-4-phenylbutyl](tetrahydro-2H-pyran-4-yl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 883726-65-6 CAPLUS

CN Carbamic acid, [(3S)-3-[[(7-ethyl-3,4-dihydro-1-methyl-2,2-dioxido-1H-pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepin-9-yl)carbonyl]amino]-2-oxo-4-phenylbutyl][(3-methoxyphenyl)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:364095 CAPLUS
DOCUMENT NUMBER: 144:390951
TITLE: Heterocyclic ketone compounds for treating Alzheimer's disease
INVENTOR(S): Demont, Emmanuel Hubert; Redshaw, Sally; Walter, Daryl Simon
PATENT ASSIGNEE(S): Glaxo Group Ltd., UK
SOURCE: PCT Int. Appl., 24 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006040149	A1	20060420	WO 2005-EP11002	20051011
WO 2006040149	A9	20060824		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: GB 2004-22765 A 20041013
OTHER SOURCE(S): MARPAT 144:390951
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Compds. of formula I [R1 = halogen or C1-3 alkyl; R2 = C1-3 alkyl, C2-4 alkenyl, C2-4 alkynyl, etc.; m = 0-4; n = 0-2; A-B = -NR5SO2-; R5 = H, C1-6 alkyl, C3-6 alkenyl, etc.; W = -CH2-, -(CH2)2-, -(CH2)3-, etc.; X-Y-Z = -C=CR8NR9-; R8 = H, C1-6 alkyl or C3-10 cycloalkyl; R9 = H, C1-6 alkyl, C1-6 alkoxy, etc.; R3 = C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, etc.; R4 = H, C1-10 alkyl, C3-10 alkenyl, etc.], having Asp2 (β-secretase, BACE1 or Memapsin-2) inhibitory activity, are prepared and may be used in the treatment of diseases characterized by elevated β- amyloid levels or β-amyloid deposits, particularly Alzheimer's disease. Thus, compound II was Boc-protected with di-tert-butoxy dicarbonate and oxidized with Dess-Martin periodinane to provide III. Compound III was then Boc-deprotected to afford title compound IV·p-MeC6H4SO3H. Compound IV·p-MeC6H4SO3H was tested in the Asp-2 inhibitory assay and the Cathepsin D inhibitory assay and exhibited inhibition <10 μM in the Asp-2 inhibitory assay and >10 fold selectivity for Asp2 over CatD.
IT 883565-28-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclic ketone compds. for the treatment of diseases characterized by elevated β-amyloid levels or β-amyloid deposits, particularly Alzheimer's disease)

RN 883565-28-4 CAPLUS

CN Pyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxamide, 6-ethyl-1,3,4,6-tetrahydro-1-methyl-N-[(1S)-2-oxo-1-(phenylmethyl)-3-[(tetrahydro-2H-pyran-4-yl)amino]propyl]-, 2,2-dioxide, mono(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)

CM 1

CRN 883565-27-3
CMF C29 H36 N4 O5 S

Absolute stereochemistry.



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



IT 856696-25-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of heterocyclic ketone compds. for the treatment of diseases characterized by elevated β-amyloid levels or β-amyloid deposits, particularly Alzheimer's disease)

RN 856696-25-8 CAPLUS

CN Pyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxamide, 6-ethyl-1,3,4,6-tetrahydro-N-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[(tetrahydro-2H-pyran-4-yl)amino]propyl]-1-methyl-, 2,2-dioxide (CA INDEX NAME)

Absolute stereochemistry.



IT 883565-25-1P 883565-26-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of heterocyclic ketone compds. for the treatment of diseases characterized by elevated β-amyloid levels or β-amyloid deposits, particularly Alzheimer's disease)

RN 883565-25-1 CAPLUS
CN Carbamic acid, [(2R,3S)-3-[[(6-ethyl-1,3,4,6-tetrahydro-1-methyl-2,2-dioxidopyrrolo[4,3,2-ef]-2,1-benzothiazepin-8-yl)carbonyl]amino]-2-hydroxy-4-phenylbutyl](tetrahydro-2H-pyran-4-yl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 883565-26-2 CAPLUS
CN Carbamic acid, [(3S)-3-[[(6-ethyl-1,3,4,6-tetrahydro-1-methyl-2,2-dioxidopyrrolo[4,3,2-ef]-2,1-benzothiazepin-8-yl)carbonyl]amino]-2-oxo-4-phenylbutyl](tetrahydro-2H-pyran-4-yl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:564675 CAPLUS
DOCUMENT NUMBER: 143:97337
TITLE: Preparation of tricyclic indole hydroxyethylamine derivatives and their use in the treatment of Alzheimer's disease
INVENTOR(S): Redshaw, Sally; Demont, Emmanuel Hubert; Walter, Daryl Simon
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 61 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005058915	A1	20050630	WO 2004-EP14076	20041209
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004299231	A1	20050630	AU 2004-299231	20041209
CA 2549072	A1	20050630	CA 2004-2549072	20041209
EP 1692143	A1	20060823	EP 2004-803724	20041209
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR, IS				
CN 1914214	A	20070214	CN 2004-80041643	20041209
BR 2004017476	A	20070508	BR 2004-17476	20041209
JP 2007513913	T	20070531	JP 2006-543488	20041209
IN 2006DN02954	A	20070810	IN 2006-DN2954	20060523
US 20070073060	A1	20070329	US 2006-596296	20060608
MX 2006PA06572	A	20060731	MX 2006-PA6572	20060609
NO 2006003137	A	20060831	NO 2006-3137	20060706

PRIORITY APPLN. INFO.: GB 2003-28900 A 20031212
WO 2004-EP14076 W 20041209
OTHER SOURCE(S): CASREACT 143:97337; MARPAT 143:97337
GI



I

AB The present invention relates to novel hydroxyethylamine compds. having Asp2 (β-secretase, BACE1 or Memapsin) inhibitory activity of formula I, processes for their preparation, to compns. containing them and to their use in the treatment of diseases characterized by elevated β-amyloid levels or β-amyloid deposits, particularly Alzheimer's disease (no data). The variables for I are A-B = -NR5-SO2- or -NR5-CO-; R5 = H, alkyl, alkenyl, alkynyl, cycloalkyl, alkylaryl, alkyl-heteroaryl, alkyl-heterocyclyl, cycloalkyl-aryl or cycloalkyl-heteroaryl; -W- = -CH2-, -(CH2)2-, -(CH2)3-, -C(H)=C(H)- or -CH2-C(H)=C(H)-; X-Y-Z = -C=CR8-NR9-; R8 = H, C1-6 alkyl or C3-10 cycloalkyl; R9 = any group given for R5, COOR12a, OR12a, OONR12aR13a, SO2NR12aR13a, CO-alkyl, CO-rings, SO2-alkyl and -SO2-rings (wherein R12a and R13a independently represent H, C1-6 alkyl or C3-10 cycloalkyl); R3 = alkyl, alkenyl, alkynyl, alkyl-cycloalkyl, alkylaryl, alkylheteroaryl or alkylheterocyclyl; R4 = any group given for R3, other ring systems, C(RaRb), CONH-alkyl, C(RaRb)-CONH-alkyl/ring, alkyl-S-C alkyl, C2-6 alkyl-NRcRd, C(RaRb)-alkyl/ring, alkyl-O-alkylaryl/alkyl/ring ; Ra and Rb independently = H, C1-6 alkyl or Ra and Rb together with the carbon atom to which they are attached may form a C3-10 cycloalkyl or heterocyclyl group; Rc and Rd independently = H, C1-6 alkyl, C3-10 cycloalkyl or Rc and Rd together with the nitrogen atom to which they are attached form a heterocyclyl group; or a pharmaceutically acceptable salt or solvate thereof.

IT 856696-23-6P, 6-Ethyl-N-[(1S,2R)-2-hydroxy-3-[[[3-(methyloxy)phenyl]methyl]amino]-1-(phenylmethyl)propyl]-1-methyl-1,3,4,6-tetrahydro-[1,2]thiazepino[5,4,3-cd]indole-8-carboxamide 2,2-dioxide 856696-25-8P, 6-Ethyl-N-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[(tetrahydro-2H-pyran-4-yl)amino]propyl]-1-methyl-1,3,4,6-tetrahydro-[1,2]thiazepino[5,4,3-cd]indole-8-carboxamide 2,2-dioxide 856696-29-2P, 6-Ethyl-N-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[[[1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl]methyl]amino]propyl]-1-methyl-1,3,4,6-tetrahydro-[1,2]thiazepino[5,4,3-cd]indole-8-carboxamide 2,2-dioxide formate 856696-31-6P, 6-Ethyl-N-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[(phenylmethyl)amino]propyl]-1-methyl-1,3,4,6-tetrahydro-[1,2]thiazepino[5,4,3-cd]indole-8-carboxamide 2,2-dioxide formate 856696-33-8P, 6-Ethyl-N-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[(4-pyridinylmethyl)amino]propyl]-1-methyl-1,3,4,6-tetrahydro-[1,2]thiazepino[5,4,3-cd]indole-8-carboxamide 2,2-dioxide formate 856696-35-0P, 6-Ethyl-N-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[(3-pyridinylmethyl)amino]propyl]-1-methyl-1,3,4,6-tetrahydro-[1,2]thiazepino[5,4,3-cd]indole-8-carboxamide 2,2-dioxide formate 856696-37-2P 856696-38-3P, 6-Ethyl-N-[(1S,2R)-3-[[(3-ethyl-5-isoxazolyl)methyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-1-methyl-1,3,4,6-tetrahydro-[1,2]thiazepino[5,4,3-cd]indole-8-carboxamide 2,2-dioxide 856696-40-7P, N-[(1S,2R)-3-(Cyclobutylamino)-2-hydroxy-1-(phenylmethyl)propyl]-6-ethyl-1-methyl-1,3,4,6-tetrahydro-[1,2]thiazepino[5,4,3-cd]indole-8-carboxamide 2,2-dioxide formate 856696-42-9P, N-[(1S,2R)-3-[(4,4-Difluorocyclohexyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-6-ethyl-1-methyl-1,3,4,6-tetrahydro-[1,2]thiazepino[5,4,3-cd]indole-8-carboxamide 2,2-dioxide formate 856696-44-1P, 6-Ethyl-N-[(1S,2R)-3-[(2-fluoroethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-1-methyl-1,3,4,6-tetrahydro-[1,2]thiazepino[5,4,3-cd]indole-8-carboxamide 2,2-dioxide formate

856696-45-2P, 6-Ethyl-N-[(1S,2R)-2-hydroxy-3-[(2,2,3,3,3-pentafluoropropyl)amino]-1-(phenylmethyl)propyl]-1-methyl-1,3,4,6-tetrahydro-[1,2]thiazepino[5,4,3-cd]indole-8-carboxamide 2,2-dioxide 856696-47-4P, 6-Ethyl-N-[(1S,2R)-3-[[(5-ethyl-3-thienyl)methyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-1-methyl-1,3,4,6-tetrahydro-[1,2]thiazepino[5,4,3-cd]indole-8-carboxamide 2,2-dioxide formate 856696-49-6P, 6-Ethyl-N-[(1S,2R)-2-hydroxy-3-[[2-(methyloxy)ethyl]amino]-1-(phenylmethyl)propyl]-1-methyl-1,3,4,6-tetrahydro-[1,2]thiazepino[5,4,3-cd]indole-8-carboxamide 2,2-dioxide formate 856696-50-9P, 6-Ethyl-N-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[(2,2,2-trifluoroethyl)amino]propyl]-1-methyl-1,3,4,6-tetrahydro-[1,2]thiazepino[5,4,3-cd]indole-8-carboxamide 2,2-dioxide 856696-52-1P, 6-Ethyl-N-[(1S,2R)-3-(ethylamino)-2-hydroxy-1-(phenylmethyl)propyl]-1-methyl-1,3,4,6-tetrahydro-[1,2]thiazepino[5,4,3-cd]indole-8-carboxamide 2,2-dioxide formate 856696-54-3P, N-[(1S,2R)-3-[(Cyclopropylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-6-ethyl-1-methyl-1,3,4,6-tetrahydro-[1,2]thiazepino[5,4,3-cd]indole-8-carboxamide 2,2-dioxide formate 856696-56-5P, N-[(1S,2R)-3-(Cyclohexylamino)-2-hydroxy-1-(phenylmethyl)propyl]-6-ethyl-1-methyl-1,3,4,6-tetrahydro-[1,2]thiazepino[5,4,3-cd]indole-8-carboxamide 2,2-dioxide formate 856696-58-7P, N-[(1S,2R)-3-(3-Cyclopenten-1-ylamino)-2-hydroxy-1-(phenylmethyl)propyl]-6-ethyl-1-methyl-1,3,4,6-tetrahydro-[1,2]thiazepino[5,4,3-cd]indole-8-carboxamide 2,2-dioxide formate 856696-60-1P, 6-Ethyl-N-[(1S,2R)-3-[[2-(ethylthio)ethyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-1-methyl-1,3,4,6-tetrahydro-[1,2]thiazepino[5,4,3-cd]indole-8-carboxamide 2,2-dioxide formate 856696-62-3P, 6-Ethyl-N-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[[[3-(trifluoromethyl)phenyl]methyl]amino]propyl]-1-methyl-1,3,4,6-tetrahydro-[1,2]thiazepino[5,4,3-cd]indole-8-carboxamide 2,2-dioxide formate 856696-64-5P, 6-Ethyl-N-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[(1-propylbutyl)amino]propyl]-1-methyl-1,3,4,6-tetrahydro-[1,2]thiazepino[5,4,3-cd]indole-8-carboxamide 2,2-dioxide formate 856696-66-7P, N-[(1S,2R)-3-[(4,4-Dimethylcyclohexyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-6-ethyl-1-methyl-1,3,4,6-tetrahydro-[1,2]thiazepino[5,4,3-cd]indole-8-carboxamide 2,2-dioxide formate 856696-67-8P, 6-Ethyl-N-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-(2-propyn-1-ylamino)propyl]-1-methyl-1,3,4,6-tetrahydro-[1,2]thiazepino[5,4,3-cd]indole-8-carboxamide 2,2-dioxide 856696-69-0P, 6-Ethyl-N-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-(2-propen-1-ylamino)propyl]-1-methyl-1,3,4,6-tetrahydro-[1,2]thiazepino[5,4,3-cd]indole-8-carboxamide 2,2-dioxide formate 856696-71-4P, N-[(1S,2R)-3-[(3,3-Dimethylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-6-ethyl-1-methyl-1,3,4,6-tetrahydro-[1,2]thiazepino[5,4,3-cd]indole-8-carboxamide 2,2-dioxide formate 856696-73-6P, 6-Ethyl-N-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[(3,3,5,5-tetramethylcyclohexyl)amino]propyl]-1-methyl-1,3,4,6-tetrahydro-[1,2]thiazepino[5,4,3-cd]indole-8-carboxamide 2,2-dioxide formate 856696-74-7P 856696-75-8P, 6-Ethyl-N-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-(propylamino)propyl]-1-methyl-1,3,4,6-tetrahydro-[1,2]thiazepino[5,4,3-cd]indole-8-carboxamide 2,2-dioxide 856696-76-9P, 6-Ethyl-N-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[(3,3,3-trifluoropropyl)amino]propyl]-1-methyl-1,3,4,6-tetrahydro-[1,2]thiazepino[5,4,3-cd]indole-8-carboxamide 2,2-dioxide 856696-77-0P, N-[(1S,2R)-3-[(2,2-Difluoroethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-6-ethyl-1-methyl-1,3,4,6-tetrahydro-

[1,2]thiazepino[5,4,3-cd]indole-8-carboxamide 2,2-dioxide 856696-79-2P, 6-Ethyl-N-[(1S,2R)-3-[(2-ethylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-1-methyl-1,3,4,6-tetrahydro-[1,2]thiazepino[5,4,3-cd]indole-8-carboxamide 2,2-dioxide formate 856696-81-6P, 6-Ethyl-N-[(1S,2R)-2-hydroxy-3-[(3-methylbutyl)amino]-1-(phenylmethyl)propyl]-1-methyl-1,3,4,6-tetrahydro-[1,2]thiazepino[5,4,3-cd]indole-8-carboxamide 2,2-dioxide formate 856696-83-8P, 6-Ethyl-N-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[(2,2,6,6-tetramethylcyclohexyl)amino]propyl]-1-methyl-1,3,4,6-tetrahydro-[1,2]thiazepino[5,4,3-cd]indole-8-carboxamide 2,2-dioxide formate 856696-85-0P 856696-86-1P, 6-Ethyl-N-[(1S,2R)-2-hydroxy-3-[[2-(methylthio)ethyl]amino]-1-(phenylmethyl)propyl]-1-methyl-1,3,4,6-tetrahydro-[1,2]thiazepino[5,4,3-cd]indole-8-carboxamide 2,2-dioxide 856696-87-2P 856696-89-4P, 6-Ethyl-N-[[(1S,2R)-2-hydroxy-3-[(2-methyl-2-propen-1-yl)amino]-1-(phenylmethyl)propyl]methyl]-1,3,4,6-tetrahydro-[1,2]thiazepino[5,4,3-cd]indole-8-carboxamide 2,2-dioxide formate 856696-91-8P, N-[(1S,2R)-3-(3-Buten-1-ylamino)-2-hydroxy-1-(phenylmethyl)propyl]-6-ethyl-1-methyl-1,3,4,6-tetrahydro-[1,2]thiazepino[5,4,3-cd]indole-8-carboxamide 2,2-dioxide formate 856696-92-9P, N-[(1S,2R)-3-(Cycloheptylamino)-2-hydroxy-1-(phenylmethyl)propyl]-6-ethyl-1-methyl-1,3,4,6-tetrahydro-[1,2]thiazepino[5,4,3-cd]indole-8-carboxamide 2,2-dioxide 856696-93-0P 856696-94-1P 856696-96-3P, 6-Ethyl-N-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[[2-(propyloxy)ethyl]amino]propyl]-1-methyl-1,3,4,6-tetrahydro-[1,2]thiazepino[5,4,3-cd]indole-8-carboxamide 2,2-dioxide formate 856696-98-5P, 6-Ethyl-N-[(1S,2R)-3-[(1-ethynylcyclohexyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-1-methyl-1,3,4,6-tetrahydro-[1,2]thiazepino[5,4,3-cd]indole-8-carboxamide 2,2-dioxide formate 856696-99-6P, 6-Ethyl-N-[(1S,2R)-2-hydroxy-3-[(4-methylphenyl)amino]-1-(phenylmethyl)propyl]-1-methyl-1,3,4,6-tetrahydro-[1,2]thiazepino[5,4,3-cd]indole-8-carboxamide 2,2-dioxide 856697-01-3P, 6-Ethyl-N-[(1S,2R)-2-hydroxy-3-[(1-methylcyclohexyl)amino]-1-(phenylmethyl)propyl]-1-methyl-1,3,4,6-tetrahydro-[1,2]thiazepino[5,4,3-cd]indole-8-carboxamide 2,2-dioxide formate 856697-03-5P, 6-Ethyl-N-[(1S,2R)-3-[(1-ethylcyclohexyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-1-methyl-1,3,4,6-tetrahydro-[1,2]thiazepino[5,4,3-cd]indole-8-carboxamide 2,2-dioxide formate 856697-05-7P, 6-Ethyl-N-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[(1-propylcyclohexyl)amino]propyl]-1-methyl-1,3,4,6-tetrahydro-[1,2]thiazepino[5,4,3-cd]indole-8-carboxamide 2,2-dioxide formate 856697-07-9P, N-[(1S,2R)-3-[[2-[(1,1-Dimethylethyl)thio]ethyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-6-ethyl-1-methyl-1,3,4,6-tetrahydro-[1,2]thiazepino[5,4,3-cd]indole-8-carboxamide 2,2-dioxide formate 856697-09-1P, 6-Ethyl-N-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[[2-[(2,2,2-trifluoroethyl)oxy]ethyl]amino]propyl]-1-methyl-1,3,4,6-tetrahydro-[1,2]thiazepino[5,4,3-cd]indole-8-carboxamide 2,2-dioxide formate 856697-11-5P, 6-Ethyl-N-[(1S,2R)-2-hydroxy-3-(phenylamino)-1-(phenylmethyl)propyl]-1-methyl-1,3,4,6-tetrahydro-[1,2]thiazepino[5,4,3-cd]indole-8-carboxamide 2,2-dioxide formate 856697-13-7P, 6-Ethyl-N-[(1S,2R)-2-hydroxy-3-[(3-methylphenyl)amino]-1-(phenylmethyl)propyl]-1-methyl-1,3,4,6-tetrahydro-[1,2]thiazepino[5,4,3-cd]indole-8-carboxamide 2,2-dioxide formate 856697-15-9P, 6-Ethyl-N-[(1S,2R)-2-hydroxy-3-[(2-methylphenyl)amino]-1-

(phenylmethyl)propyl]-1-methyl-1,3,4,6-tetrahydro-[1,2]thiazepino[5,4,3-cd]indole-8-carboxamide 2,2-dioxide formate 856697-17-1P, 6-Ethyl-N-[(1S,2R)-3-[[(1-ethyl-1H-pyrazol-4-yl)methyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-1-methyl-1,3,4,6-tetrahydro-[1,2]thiazepino[5,4,3-cd]indole-8-carboxamide 2,2-dioxide formate 856697-19-3P, 6-Ethyl-N-[(1S,2R)-2-hydroxy-3-[(3-methyl-2-buten-1-yl)amino]-1-(phenylmethyl)propyl]-1-methyl-1,3,4,6-tetrahydro-[1,2]thiazepino[5,4,3-cd]indole-8-carboxamide 2,2-dioxide formate 856697-21-7P, 6-Butyl-N-[(1S,2R)-3-(cyclohexylamino)-2-hydroxy-1-(phenylmethyl)propyl]-1-methyl-1,3,4,6-tetrahydro-[1,2]thiazepino[5,4,3-cd]indole-8-carboxamide 2,2-dioxide formate 856697-23-9P, N-[(1S,2R)-3-[(2-Chlorophenyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-6-ethyl-1-methyl-1,3,4,6-tetrahydro-[1,2]thiazepino[5,4,3-cd]indole-8-carboxamide 2,2-dioxide formate 856697-25-1P, 6-Ethyl-N-[(1S,2R)-2-hydroxy-3-[[2-(methyloxy)phenyl]amino]-1-(phenylmethyl)propyl]-1-methyl-1,3,4,6-tetrahydro-[1,2]thiazepino[5,4,3-cd]indole-8-carboxamide 2,2-dioxide formate 856697-27-3P, 6-Ethyl-N-[(1S,2R)-2-hydroxy-3-[[4-(methyloxy)phenyl]amino]-1-(phenylmethyl)propyl]-1-methyl-1,3,4,6-tetrahydro-[1,2]thiazepino[5,4,3-cd]indole-8-carboxamide 2,2-dioxide formate 856697-29-5P, N-[(1S,2R)-3-[(3-Chlorophenyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-6-ethyl-1-methyl-1,3,4,6-tetrahydro-[1,2]thiazepino[5,4,3-cd]indole-8-carboxamide 2,2-dioxide formate 856697-31-9P, 6-Ethyl-N-[(1S,2R)-2-hydroxy-3-[[3-(methyloxy)phenyl]amino]-1-(phenylmethyl)propyl]-1-methyl-1,3,4,6-tetrahydro-[1,2]thiazepino[5,4,3-cd]indole-8-carboxamide 2,2-dioxide formate 856697-33-1P, N-[(1S,2R)-3-[(4-Chlorophenyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-6-ethyl-1-methyl-1,3,4,6-tetrahydro-[1,2]thiazepino[5,4,3-cd]indole-8-carboxamide 2,2-dioxide formate 856697-35-3P, N-[(1S,2R)-3-(Cyclohexylamino)-2-hydroxy-1-(phenylmethyl)propyl]-1-methyl-6-propyl-1,3,4,6-tetrahydro-[1,2]thiazepino[5,4,3-cd]indole-8-carboxamide 2,2-dioxide formate 856697-37-5P, N-[(1S,2R)-3-(Cyclohexylamino)-2-hydroxy-1-(phenylmethyl)propyl]-1-methyl-6-(1-methylethyl)-1,3,4,6-tetrahydro-[1,2]thiazepino[5,4,3-cd]indole-8-carboxamide 2,2-dioxide formate 856697-38-6P, N-[(1S,2R)-3-(Cyclopropylamino)-2-hydroxy-1-(phenylmethyl)propyl]-6-ethyl-1-methyl-1,3,4,6-tetrahydro-[1,2]thiazepino[5,4,3-cd]indole-8-carboxamide 2,2-dioxide 856697-40-0P, N-[(1S,2R)-2-Hydroxy-3-[[[3-(methyloxy)phenyl]methyl]amino]-1-(phenylmethyl)propyl]-1-methyl-6-propyl-1,3,4,6-tetrahydro-[1,2]thiazepino[5,4,3-cd]indole-8-carboxamide 2,2-dioxide formate 856697-42-2P, N-[(1S,2R)-3-(Cyclohexylamino)-2-hydroxy-1-(phenylmethyl)propyl]-1,6-diethyl-1,3,4,6-tetrahydro-[1,2]thiazepino[5,4,3-cd]indole-8-carboxamide 2,2-dioxide formate 856697-44-4P, N-[(1S,2R)-3-[(2,4-Dimethylphenyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-6-ethyl-1-methyl-1,3,4,6-tetrahydro-[1,2]thiazepino[5,4,3-cd]indole-8-carboxamide 2,2-dioxide formate 856697-46-6P, N-[(1S,2R)-3-[[4-(Dimethylamino)phenyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-6-ethyl-1-methyl-1,3,4,6-tetrahydro-[1,2]thiazepino[5,4,3-cd]indole-8-carboxamide 2,2-dioxide formate 856697-48-8P, N-[(1S,2R)-3-(2-Butyn-1-ylamino)-2-hydroxy-1-(phenylmethyl)propyl]-6-ethyl-1-methyl-1,3,4,6-tetrahydro-[1,2]thiazepino[5,4,3-cd]indole-8-carboxamide 2,2-dioxide formate 856697-50-2P, 6-Ethyl-N-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[(1,1,5-trimethylhexyl)amino]propyl]-1-methyl-1,3,4,6-tetrahydro-[1,2]thiazepino[5,4,3-cd]indole-8-carboxamide 2,2-dioxide formate 856697-52-4P, N-[(1S,2R)-3-(Butylamino)-2-hydroxy-1-

(phenylmethyl)propyl]-6-ethyl-1-methyl-1,3,4,6-tetrahydro-
[1,2]thiazepino[5,4,3-cd]indole-8-carboxamide 2,2-dioxide formate
856697-54-6P, N-[(1S,2R)-3-[[2,3-Bis(methyloxy)phenyl]amino]-2-
hydroxy-1-(phenylmethyl)propyl]-6-ethyl-1-methyl-1,3,4,6-tetrahydro-
[1,2]thiazepino[5,4,3-cd]indole-8-carboxamide 2,2-dioxide formate
856697-56-8P, 6-Ethyl-N-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[[[3-
[(trifluoromethyl)oxy]phenyl]methyl]amino]propyl]-1-methyl-1,3,4,6-
tetrahydro-[1,2]thiazepino[5,4,3-cd]indole-8-carboxamide 2,2-dioxide
formate 856697-58-0P, 6-Ethyl-N-[(1S,2R)-2-hydroxy-3-[[(6-methyl-
2-pyridinyl)methyl]amino]-1-(phenylmethyl)propyl]-1-methyl-1,3,4,6-
tetrahydro-[1,2]thiazepino[5,4,3-cd]indole-8-carboxamide 2,2-dioxide
formate 856697-60-4P 856697-62-6P,
6-Ethyl-N-[(1S,2R)-2-hydroxy-3-[((1R)-1-methylpropyl)amino]-1-
(phenylmethyl)propyl]-1-methyl-1,3,4,6-tetrahydro-[1,2]thiazepino[5,4,3-
cd]indole-8-carboxamide 2,2-dioxide formate 856697-64-8P,
6-Ethyl-N-[(1S,2R)-2-hydroxy-3-[((1S)-1-methylpropyl)amino]-1-
(phenylmethyl)propyl]-1-methyl-1,3,4,6-tetrahydro-[1,2]thiazepino[5,4,3-
cd]indole-8-carboxamide 2,2-dioxide formate 856697-66-0P,
6-Ethyl-N-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[(2-
pyridinylmethyl)amino]propyl]-1-methyl-1,3,4,6-tetrahydro-
[1,2]thiazepino[5,4,3-cd]indole-8-carboxamide 2,2-dioxide formate
856697-68-2P, 6-Ethyl-N-[(1S,2R)-2-hydroxy-3-[[2-methyl-4-
(methyloxy)phenyl]amino]-1-(phenylmethyl)propyl]-1-methyl-1,3,4,6-
tetrahydro-[1,2]thiazepino[5,4,3-cd]indole-8-carboxamide 2,2-dioxide
formate 856697-70-6P, 6-Ethyl-N-[(1S,2R)-3-[(1-
ethylcyclopropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-1-methyl-1,3,4,6-
tetrahydro-[1,2]thiazepino[5,4,3-cd]indole-8-carboxamide 2,2-dioxide
formate 856697-72-8P, 6-Ethyl-N-[(1S,2R)-2-hydroxy-3-(2-pentyn-1-
ylamino)-1-(phenylmethyl)propyl]-1-methyl-1,3,4,6-tetrahydro-
[1,2]thiazepino[5,4,3-cd]indole-8-carboxamide 2,2-dioxide formate
856697-74-0P, 6-Ethyl-N-[(1S,2R)-3-[(3-fluoropropyl)amino]-2-
hydroxy-1-(phenylmethyl)propyl]-1-methyl-1,3,4,6-tetrahydro-
[1,2]thiazepino[5,4,3-cd]indole-8-carboxamide 2,2-dioxide formate
856697-75-1P, 6-Ethyl-N-[(1S,2R)-2-hydroxy-3-[(1-
methylcyclopropyl)amino]-1-(phenylmethyl)propyl]-1-methyl-1,3,4,6-
tetrahydro-[1,2]thiazepino[5,4,3-cd]indole-8-carboxamide
856697-76-2P, 1,6-Diethyl-N-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-
[(tetrahydro-2H-pyran-4-yl)amino]propyl]-1,3,4,6-tetrahydro-
[1,2]thiazepino[5,4,3-cd]indole-8-carboxamide 2,2-dioxide
856697-78-4P, N-[(1S,2R)-3-[(1,1-Dimethyl-2-propyn-1-yl)amino]-2-
hydroxy-1-(phenylmethyl)propyl]-6-ethyl-1-methyl-1,3,4,6-tetrahydro-
[1,2]thiazepino[5,4,3-cd]indole-8-carboxamide 2,2-dioxide formate
856697-79-5P, N-[(1S,2R)-3-(Cyclooctylamino)-2-hydroxy-1-
(phenylmethyl)propyl]-6-ethyl-1-methyl-1,3,4,6-tetrahydro-
[1,2]thiazepino[5,4,3-cd]indole-8-carboxamide 2,2-dioxide
857052-39-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(drug candidate; preparation of tricyclic indole hydroxyethylamine derivs.
and their use in treatment of Alzheimer's disease)

RN 856696-23-6 CAPLUS
CN Pyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxamide,
6-ethyl-1,3,4,6-tetrahydro-N-[(1S,2R)-2-hydroxy-3-[[(3-
methoxyphenyl)methyl]amino]-1-(phenylmethyl)propyl]-1-methyl-, 2,2-dioxide
(CA INDEX NAME)

Absolute stereochemistry.



RN 856696-25-8 CAPLUS
CN Pyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxamide, 6-ethyl-1,3,4,6-tetrahydro-N-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[(tetrahydro-2H-pyran-4-yl)amino]propyl]-1-methyl-, 2,2-dioxide (CA INDEX NAME)

Absolute stereochemistry.



RN 856696-29-2 CAPLUS
CN Formic acid, compd. with 6-ethyl-1,3,4,6-tetrahydro-N-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[[[1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl]methyl]amino]propyl]-1-methylpyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 856696-28-1
CMF C30 H35 F3 N6 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2



RN 856696-31-6 CAPLUS
CN Formic acid, compd. with 6-ethyl-1,3,4,6-tetrahydro-N-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[(phenylmethyl)amino]propyl]-1-methylpyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 856696-30-5
CMF C31 H36 N4 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 856696-33-8 CAPLUS
CN Formic acid, compd. with 6-ethyl-1,3,4,6-tetrahydro-N-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[(4-pyridinylmethyl)amino]propyl]-1-methylpyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 856696-32-7
CMF C30 H35 N5 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 856696-35-0 CAPLUS
CN Formic acid, compd. with 6-ethyl-1,3,4,6-tetrahydro-N-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[(3-pyridinylmethyl)amino]propyl]-1-methylpyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 856696-34-9
CMF C30 H35 N5 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2



RN 856696-37-2 CAPLUS
CN Formic acid, compd. with 6-ethyl-1,3,4,6-tetrahydro-N-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[(tetrahydro-2,2-dimethyl-2H-pyran-4-yl)amino]propyl]-1-methylpyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 856696-36-1
CMF C31 H42 N4 O5 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 856696-38-3 CAPLUS
CN Pyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxamide, 6-ethyl-N-[(1S,2R)-3-[[(3-ethyl-5-isoxazolyl)methyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-1,3,4,6-tetrahydro-1-methyl-, 2,2-dioxide (CA INDEX NAME)

Absolute stereochemistry.



RN 856696-40-7 CAPLUS
CN Formic acid, compd. with N-[(1S,2R)-3-(cyclobutylamino)-2-hydroxy-1-(phenylmethyl)propyl]-6-ethyl-1,3,4,6-tetrahydro-1-methylpyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 856696-39-4
CMF C28 H36 N4 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 856696-42-9 CAPLUS
CN Formic acid, compd. with N-[(1S,2R)-3-[(4,4-difluorocyclohexyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-6-ethyl-1,3,4,6-tetrahydro-1-methylpyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 856696-41-8
CMF C30 H38 F2 N4 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 856696-44-1 CAPLUS
CN Formic acid, compd. with 6-ethyl-N-[(1S,2R)-3-[(2-fluoroethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-1,3,4,6-tetrahydro-1-methylpyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 856696-43-0
CMF C26 H33 F N4 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2



RN 856696-45-2 CAPLUS
CN Pyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxamide, 6-ethyl-1,3,4,6-tetrahydro-N-[(1S,2R)-2-hydroxy-3-[(2,2,3,3,3-pentafluoropropyl)amino]-1-(phenylmethyl)propyl]-1-methyl-, 2,2-dioxide (CA INDEX NAME)

Absolute stereochemistry.



RN 856696-47-4 CAPLUS
CN Formic acid, compd. with 6-ethyl-N-[(1S,2R)-3-[[(5-ethyl-3-thienyl)methyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-1,3,4,6-tetrahydro-1-methylpyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 856696-46-3
CMF C31 H38 N4 O4 S2

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2



RN 856696-49-6 CAPLUS
CN Formic acid, compd. with 6-ethyl-1,3,4,6-tetrahydro-N-[(1S,2R)-2-hydroxy-3-[(2-methoxyethyl)amino]-1-(phenylmethyl)propyl]-1-methylpyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 856696-48-5
CMF C27 H36 N4 O5 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 856696-50-9 CAPLUS
CN Pyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxamide, 6-ethyl-1,3,4,6-tetrahydro-N-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[(2,2,2-trifluoroethyl)amino]propyl]-1-methyl-, 2,2-dioxide (CA INDEX NAME)

Absolute stereochemistry.



RN 856696-52-1 CAPLUS
CN Formic acid, compd. with 6-ethyl-N-[(1S,2R)-3-(ethylamino)-2-hydroxy-1-(phenylmethyl)propyl]-1,3,4,6-tetrahydro-1-methylpyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 856696-51-0
CMF C26 H34 N4 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 856696-54-3 CAPLUS
CN Formic acid, compd. with N-[(1S,2R)-3-[(cyclopropylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-6-ethyl-1,3,4,6-tetrahydro-1-methylpyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 856696-53-2
CMF C28 H36 N4 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 856696-56-5 CAPLUS
CN Formic acid, compd. with N-[(1S,2R)-3-(cyclohexylamino)-2-hydroxy-1-(phenylmethyl)propyl]-6-ethyl-1,3,4,6-tetrahydro-1-methylpyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 856696-55-4
CMF C30 H40 N4 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2



RN 856696-58-7 CAPLUS
CN Formic acid, compd. with N-[(1S,2R)-3-(3-cyclopenten-1-ylamino)-2-hydroxy-1-(phenylmethyl)propyl]-6-ethyl-1,3,4,6-tetrahydro-1-methylpyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 856696-57-6
CMF C29 H36 N4 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 856696-60-1 CAPLUS
CN Formic acid, compd. with 6-ethyl-N-[(1S,2R)-3-[[2-(ethylthio)ethyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-1,3,4,6-tetrahydro-1-methylpyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 856696-59-8
CMF C28 H38 N4 O4 S2

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 856696-62-3 CAPLUS
CN Formic acid, compd. with 6-ethyl-1,3,4,6-tetrahydro-N-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[[[3-(trifluoromethyl)phenyl]methyl]amino]propyl]-1-methylpyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 856696-61-2
CMF C32 H35 F3 N4 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2



RN 856696-64-5 CAPLUS
CN Formic acid, compd. with 6-ethyl-1,3,4,6-tetrahydro-N-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[(1-propylbutyl)amino]propyl]-1-methylpyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 856696-63-4
CMF C31 H44 N4 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 856696-66-7 CAPLUS
CN Formic acid, compd. with N-[(1S,2R)-3-[(4,4-dimethylcyclohexyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-6-ethyl-1,3,4,6-tetrahydro-1-methylpyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 856696-65-6
CMF C32 H44 N4 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 856696-67-8 CAPLUS
CN Pyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxamide, 6-ethyl-1,3,4,6-tetrahydro-N-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-(2-propyn-1-ylamino)propyl]-1-methyl-, 2,2-dioxide (CA INDEX NAME)

Absolute stereochemistry.



RN 856696-69-0 CAPLUS
CN Formic acid, compd. with 6-ethyl-1,3,4,6-tetrahydro-N-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-(2-propen-1-ylamino)propyl]-1-methylpyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 856696-68-9
CMF C27 H34 N4 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2



RN 856696-71-4 CAPLUS
CN Formic acid, compd. with N-[(1S,2R)-3-[(3,3-dimethylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-6-ethyl-1,3,4,6-tetrahydro-1-methylpyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 856696-70-3

CMF C30 H42 N4 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2



RN 856696-73-6 CAPLUS
CN Formic acid, compd. with 6-ethyl-1,3,4,6-tetrahydro-N-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[(3,3,5,5-tetramethylcyclohexyl)amino]propyl]-1-methylpyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 856696-72-5
CMF C34 H48 N4 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2



RN 856696-74-7 CAPLUS
CN Pyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxamide, N-[(1S,2R)-3-[(1,5-dimethylhexyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-6-ethyl-1,3,4,6-tetrahydro-1-methyl-, 2,2-dioxide (CA INDEX NAME)

Absolute stereochemistry.



RN 856696-75-8 CAPLUS
CN Pyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxamide, 6-ethyl-1,3,4,6-tetrahydro-N-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-(propylamino)propyl]-1-methyl-, 2,2-dioxide (CA INDEX NAME)

Absolute stereochemistry.



RN 856696-76-9 CAPLUS
CN Pyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxamide, 6-ethyl-1,3,4,6-tetrahydro-N-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[(3,3,3-trifluoropropyl)amino]propyl]-1-methyl-, 2,2-dioxide (CA INDEX NAME)

Absolute stereochemistry.



RN 856696-77-0 CAPLUS
CN Pyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxamide, N-[(1S,2R)-3-[(2,2-difluoroethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-6-ethyl-1,3,4,6-tetrahydro-1-methyl-, 2,2-dioxide (CA INDEX NAME)

Absolute stereochemistry.



RN 856696-79-2 CAPLUS
CN Formic acid, compd. with 6-ethyl-N-[(1S,2R)-3-[(2-ethylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-1,3,4,6-tetrahydro-1-methylpyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 856696-78-1
CMF C30 H42 N4 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2



RN 856696-81-6 CAPLUS
CN Formic acid, compd. with 6-ethyl-1,3,4,6-tetrahydro-N-[(1S,2R)-2-hydroxy-3-[(3-methylbutyl)amino]-1-(phenylmethyl)propyl]-1-methylpyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 856696-80-5
CMF C29 H40 N4 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 856696-83-8 CAPLUS
CN Formic acid, compd. with 6-ethyl-1,3,4,6-tetrahydro-N-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[(2,2,6,6-tetramethylcyclohexyl)amino]propyl]-1-methylpyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 856696-82-7
CMF C34 H48 N4 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 856696-85-0 CAPLUS
CN Formic acid, compd. with N-[(1S,2R)-3-[(2,2-dimethylcyclohexyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-6-ethyl-1,3,4,6-tetrahydro-1-methylpyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 856696-84-9
CMF C32 H44 N4 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2



RN 856696-86-1 CAPLUS
CN Pyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxamide, 6-ethyl-1,3,4,6-tetrahydro-N-[(1S,2R)-2-hydroxy-3-[[2-(methylthio)ethyl]amino]-1-(phenylmethyl)propyl]-1-methyl-, 2,2-dioxide (CA INDEX NAME)

Absolute stereochemistry.



RN 856696-87-2 CAPLUS
CN Pyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxamide, N-[(1S,2R)-3-[(2-cyclohexylethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-6-ethyl-1,3,4,6-tetrahydro-1-methyl-, 2,2-dioxide (CA INDEX NAME)

Absolute stereochemistry.



RN 856696-89-4 CAPLUS
CN Formic acid, compd. with 6-ethyl-1,3,4,6-tetrahydro-N-[(1S,2R)-2-hydroxy-3-[(2-methyl-2-propen-1-yl)amino]-1-(phenylmethyl)propyl]-1-methylpyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 856696-88-3
CMF C28 H36 N4 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2



RN 856696-91-8 CAPLUS
CN Formic acid, compd. with N-[(1S,2R)-3-(3-buten-1-ylamino)-2-hydroxy-1-(phenylmethyl)propyl]-6-ethyl-1,3,4,6-tetrahydro-1-methylpyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 856696-90-7
CMF C28 H36 N4 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2



RN 856696-92-9 CAPLUS
CN Pyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxamide, N-[(1S,2R)-3-(cycloheptylamino)-2-hydroxy-1-(phenylmethyl)propyl]-6-ethyl-1,3,4,6-tetrahydro-1-methyl-, 2,2-dioxide (CA INDEX NAME)

Absolute stereochemistry.



RN 856696-93-0 CAPLUS
CN Pyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxamide, 6-ethyl-1,3,4,6-tetrahydro-N-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-(tricyclo[3.3.1.13,7]dec-2-ylamino)propyl]-1-methyl-, 2,2-dioxide (CA INDEX NAME)

Absolute stereochemistry.



RN 856696-94-1 CAPLUS
CN Pyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxamide, N-[(1S,2R)-3-[(1R,4S)-bicyclo[2.2.1]hept-2-ylamino]-2-hydroxy-1-(phenylmethyl)propyl]-6-ethyl-1,3,4,6-tetrahydro-1-methyl-, 2,2-dioxide (CA INDEX NAME)

Absolute stereochemistry.



RN 856696-96-3 CAPLUS
CN Formic acid, compd. with 6-ethyl-1,3,4,6-tetrahydro-N-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[(2-propoxyethyl)amino]propyl]-1-methylpyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 856696-95-2
CMF C29 H40 N4 O5 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2



RN 856696-98-5 CAPLUS
CN Formic acid, compd. with 6-ethyl-N-[(1S,2R)-3-[(1-ethynylcyclohexyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-1,3,4,6-tetrahydro-1-methylpyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 856696-97-4
CMF C32 H40 N4 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

RN 856696-99-6 CAPLUS
CN Pyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxamide, 6-ethyl-1,3,4,6-tetrahydro-N-[(1S,2R)-2-hydroxy-3-[(4-methylphenyl)amino]-1-(phenylmethyl)propyl]-1-methyl-, 2,2-dioxide (CA INDEX NAME)

Absolute stereochemistry.



RN 856697-01-3 CAPLUS
CN Formic acid, compd. with 6-ethyl-1,3,4,6-tetrahydro-N-[(1S,2R)-2-hydroxy-3-[(1-methylcyclohexyl)amino]-1-(phenylmethyl)propyl]-1-methylpyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 856697-00-2
CMF C31 H42 N4 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 856697-03-5 CAPLUS
CN Formic acid, compd. with 6-ethyl-N-[(1S,2R)-3-[(1-ethylcyclohexyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-1,3,4,6-tetrahydro-1-methylpyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 856697-02-4
CMF C32 H44 N4 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 856697-05-7 CAPLUS
CN Formic acid, compd. with 6-ethyl-1,3,4,6-tetrahydro-N-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[(1-propylcyclohexyl)amino]propyl]-1-methylpyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 856697-04-6
CMF C33 H46 N4 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2



RN 856697-07-9 CAPLUS
CN Formic acid, compd. with N-[(1S,2R)-3-[[2-[(1,1-dimethylethyl)thio]ethyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-6-ethyl-1,3,4,6-tetrahydro-1-methylpyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 856697-06-8
CMF C30 H42 N4 O4 S2

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 856697-09-1 CAPLUS
CN Formic acid, compd. with 6-ethyl-1,3,4,6-tetrahydro-N-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[[2-(2,2,2-trifluoroethoxy)ethyl]amino]propyl]-1-methylpyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 856697-08-0
CMF C28 H35 F3 N4 O5 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 856697-11-5 CAPLUS
CN Formic acid, compd. with 6-ethyl-1,3,4,6-tetrahydro-N-[(1S,2R)-2-hydroxy-3-(phenylamino)-1-(phenylmethyl)propyl]-1-methylpyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 856697-10-4
CMF C30 H34 N4 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2



RN 856697-13-7 CAPLUS
CN Formic acid, compd. with 6-ethyl-1,3,4,6-tetrahydro-N-[(1S,2R)-2-hydroxy-3-[(3-methylphenyl)amino]-1-(phenylmethyl)propyl]-1-methylpyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 856697-12-6
CMF C31 H36 N4 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 856697-15-9 CAPLUS
CN Formic acid, compd. with 6-ethyl-1,3,4,6-tetrahydro-N-[(1S,2R)-2-hydroxy-3-[(2-methylphenyl)amino]-1-(phenylmethyl)propyl]-1-methylpyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 856697-14-8
CMF C31 H36 N4 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 856697-17-1 CAPLUS
CN Formic acid, compd. with 6-ethyl-N-[(1S,2R)-3-[[(1-ethyl-1H-pyrazol-4-yl)methyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-1,3,4,6-tetrahydro-1-methylpyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 856697-16-0
CMF C30 H38 N6 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2



RN 856697-19-3 CAPLUS
CN Formic acid, compd. with 6-ethyl-1,3,4,6-tetrahydro-N-[(1S,2R)-2-hydroxy-3-[(3-methyl-2-buten-1-yl)amino]-1-(phenylmethyl)propyl]-1-methylpyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 856697-18-2
CMF C29 H38 N4 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2



RN 856697-21-7 CAPLUS
CN Formic acid, compd. with 6-butyl-N-[(1S,2R)-3-(cyclohexylamino)-2-hydroxy-1-(phenylmethyl)propyl]-1,3,4,6-tetrahydro-1-methylpyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 856697-20-6
CMF C32 H44 N4 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2



RN 856697-23-9 CAPLUS
CN Formic acid, compd. with N-[(1S,2R)-3-[(2-chlorophenyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-6-ethyl-1,3,4,6-tetrahydro-1-methylpyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 856697-22-8
CMF C30 H33 Cl N4 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2



RN 856697-25-1 CAPLUS
CN Formic acid, compd. with 6-ethyl-1,3,4,6-tetrahydro-N-[(1S,2R)-2-hydroxy-3-[(2-methoxyphenyl)amino]-1-(phenylmethyl)propyl]-1-methylpyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 856697-24-0
CMF C31 H36 N4 O5 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 856697-27-3 CAPLUS
CN Formic acid, compd. with 6-ethyl-1,3,4,6-tetrahydro-N-[(1S,2R)-2-hydroxy-3-[(4-methoxyphenyl)amino]-1-(phenylmethyl)propyl]-1-methylpyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 856697-26-2
CMF C31 H36 N4 O5 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 856697-29-5 CAPLUS
CN Formic acid, compd. with N-[(1S,2R)-3-[(3-chlorophenyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-6-ethyl-1,3,4,6-tetrahydro-1-methylpyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 856697-28-4
CMF C30 H33 Cl N4 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2



RN 856697-31-9 CAPLUS
CN Formic acid, compd. with 6-ethyl-1,3,4,6-tetrahydro-N-[(1S,2R)-2-hydroxy-3-[(3-methoxyphenyl)amino]-1-(phenylmethyl)propyl]-1-methylpyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 856697-30-8
CMF C31 H36 N4 O5 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 856697-33-1 CAPLUS
CN Formic acid, compd. with N-[(1S,2R)-3-[(4-chlorophenyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-6-ethyl-1,3,4,6-tetrahydro-1-methylpyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 856697-32-0
CMF C30 H33 Cl N4 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 856697-35-3 CAPLUS
CN Formic acid, compd. with N-[(1S,2R)-3-(cyclohexylamino)-2-hydroxy-1-(phenylmethyl)propyl]-1,3,4,6-tetrahydro-1-methyl-6-propylpyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 856697-34-2
CMF C31 H42 N4 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2



RN 856697-37-5 CAPLUS
CN Formic acid, compd. with N-[(1S,2R)-3-(cyclohexylamino)-2-hydroxy-1-(phenylmethyl)propyl]-1,3,4,6-tetrahydro-1-methyl-6-(1-methylethyl)pyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 856697-36-4
CMF C31 H42 N4 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2



RN 856697-38-6 CAPLUS
CN Pyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxamide, N-[(1S,2R)-3-(cyclopropylamino)-2-hydroxy-1-(phenylmethyl)propyl]-6-ethyl-1,3,4,6-tetrahydro-1-methyl-, 2,2-dioxide (CA INDEX NAME)

Absolute stereochemistry.



RN 856697-40-0 CAPLUS
CN Formic acid, compd. with 1,3,4,6-tetrahydro-N-[(1S,2R)-2-hydroxy-3-[[(3-methoxyphenyl)methyl]amino]-1-(phenylmethyl)propyl]-1-methyl-6-propylpyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 856697-39-7
CMF C33 H40 N4 O5 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 856697-42-2 CAPLUS
CN Formic acid, compd. with N-[(1S,2R)-3-(cyclohexylamino)-2-hydroxy-1-(phenylmethyl)propyl]-1,6-diethyl-1,3,4,6-tetrahydropyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 856697-41-1
CMF C31 H42 N4 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 856697-44-4 CAPLUS
CN Formic acid, compd. with N-[(1S,2R)-3-[(2,4-dimethylphenyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-6-ethyl-1,3,4,6-tetrahydro-1-methylpyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 856697-43-3
CMF C32 H38 N4 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2



RN 856697-46-6 CAPLUS
CN Formic acid, compd. with N-[(1S,2R)-3-[[4-(dimethylamino)phenyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-6-ethyl-1,3,4,6-tetrahydro-1-methylpyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 856697-45-5
CMF C32 H39 N5 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 856697-48-8 CAPLUS
CN Formic acid, compd. with N-[(1S,2R)-3-(2-butyn-1-ylamino)-2-hydroxy-1-(phenylmethyl)propyl]-6-ethyl-1,3,4,6-tetrahydro-1-methylpyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 856697-47-7
CMF C28 H34 N4 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 856697-50-2 CAPLUS
CN Formic acid, compd. with 6-ethyl-1,3,4,6-tetrahydro-N-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[(1,1,5-trimethylhexyl)amino]propyl]-1-methylpyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 856697-49-9
CMF C33 H48 N4 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2



RN 856697-52-4 CAPLUS
CN Formic acid, compd. with N-[(1S,2R)-3-(butylamino)-2-hydroxy-1-(phenylmethyl)propyl]-6-ethyl-1,3,4,6-tetrahydro-1-methylpyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 856697-51-3
CMF C28 H38 N4 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 856697-54-6 CAPLUS
CN Formic acid, compd. with N-[(1S,2R)-3-[(2,3-dimethoxyphenyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-6-ethyl-1,3,4,6-tetrahydro-1-methylpyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 856697-53-5
CMF C32 H38 N4 O6 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 856697-56-8 CAPLUS
CN Formic acid, compd. with 6-ethyl-1,3,4,6-tetrahydro-N-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[[[3-(trifluoromethoxy)phenyl]methyl]amino]propyl]-1-methylpyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 856697-55-7
CMF C32 H35 F3 N4 O5 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2



RN 856697-58-0 CAPLUS
CN Formic acid, compd. with 6-ethyl-1,3,4,6-tetrahydro-N-[(1S,2R)-2-hydroxy-3-[[(6-methyl-2-pyridinyl)methyl]amino]-1-(phenylmethyl)propyl]-1-methylpyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 856697-57-9
CMF C31 H37 N5 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 856697-60-4 CAPLUS
CN Formic acid, compd. with N-[(1S,2R)-3-[[2-(cyclohexylamino)-1-methyl-2-oxoethyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-6-ethyl-1,3,4,6-tetrahydro-1-methylpyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 856697-59-1
CMF C33 H45 N5 O5 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 856697-62-6 CAPLUS
CN Formic acid, compd. with 6-ethyl-1,3,4,6-tetrahydro-N-[(1S,2R)-2-hydroxy-3-[[(1R)-1-methylpropyl]amino]-1-(phenylmethyl)propyl]-1-methylpyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 856697-61-5
CMF C28 H38 N4 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2



RN 856697-64-8 CAPLUS
CN Formic acid, compd. with 6-ethyl-1,3,4,6-tetrahydro-N-[(1S,2R)-2-hydroxy-3-[[(1S)-1-methylpropyl]amino]-1-(phenylmethyl)propyl]-1-methylpyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 856697-63-7
CMF C28 H38 N4 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 856697-66-0 CAPLUS
CN Formic acid, compd. with 6-ethyl-1,3,4,6-tetrahydro-N-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[(2-pyridinylmethyl)amino]propyl]-1-methylpyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 856697-65-9
CMF C30 H35 N5 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 856697-68-2 CAPLUS
CN Formic acid, compd. with 6-ethyl-1,3,4,6-tetrahydro-N-[(1S,2R)-2-hydroxy-3-[(4-methoxy-2-methylphenyl)amino]-1-(phenylmethyl)propyl]-1-methylpyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 856697-67-1
CMF C32 H38 N4 O5 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2



RN 856697-70-6 CAPLUS
CN Formic acid, compd. with 6-ethyl-N-[(1S,2R)-3-[(1-ethylcyclopropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-1,3,4,6-tetrahydro-1-methylpyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 856697-69-3
CMF C29 H38 N4 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 856697-72-8 CAPLUS
CN Formic acid, compd. with 6-ethyl-1,3,4,6-tetrahydro-N-[(1S,2R)-2-hydroxy-3-(2-pentyn-1-ylamino)-1-(phenylmethyl)propyl]-1-methylpyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 856697-71-7
CMF C29 H36 N4 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 856697-74-0 CAPLUS
CN Formic acid, compd. with 6-ethyl-N-[(1S,2R)-3-[(3-fluoropropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-1,3,4,6-tetrahydro-1-methylpyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 856697-73-9
CMF C27 H35 F N4 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2



RN 856697-75-1 CAPLUS
CN Pyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxamide, 6-ethyl-1,3,4,6-tetrahydro-N-[(1S,2R)-2-hydroxy-3-[(1-methylcyclopropyl)amino]-1-(phenylmethyl)propyl]-1-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 856697-76-2 CAPLUS
CN Pyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxamide, 1,6-diethyl-1,3,4,6-tetrahydro-N-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[(tetrahydro-2H-pyran-4-yl)amino]propyl]-, 2,2-dioxide (CA INDEX NAME)

Absolute stereochemistry.



RN 856697-78-4 CAPLUS
CN Formic acid, compd. with N-[(1S,2R)-3-[(1,1-dimethyl-2-propyn-1-yl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-6-ethyl-1,3,4,6-tetrahydro-1-methylpyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 856697-77-3
CMF C29 H36 N4 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2



RN 856697-79-5 CAPLUS
CN Pyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxamide, N-[(1S,2R)-3-(cyclooctylamino)-2-hydroxy-1-(phenylmethyl)propyl]-6-ethyl-1,3,4,6-tetrahydro-1-methyl-, 2,2-dioxide (CA INDEX NAME)

Absolute stereochemistry.



RN 857052-39-2 CAPLUS
CN Formic acid, compd. with 6-ethyl-1,3,4,6-tetrahydro-N-[(1S,2R)-2-hydroxy-3-[(4-methylcyclohexyl)amino]-1-(phenylmethyl)propyl]-1-methylpyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 857052-38-1
CMF C31 H42 N4 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2



IT 856695-82-4P 856695-95-9P 856695-96-0P,
6-Ethyl-1-methyl-1,3,4,6-tetrahydro-[1,2]thiazepino[5,4,3-cd]indole-8-carboxylic acid 2,2-dioxide 856696-02-1P,
1-Methyl-6-(1-methylethyl)-1,3,4,6-tetrahydro-[1,2]thiazepino[5,4,3-cd]indole-8-carboxylic acid 2,2-dioxide 856696-03-2P,
1-Methyl-6-propyl-1,3,4,6-tetrahydro-[1,2]thiazepino[5,4,3-cd]indole-8-carboxylic acid 2,2-dioxide 856696-04-3P,
6-Butyl-1-methyl-1,3,4,6-tetrahydro-[1,2]thiazepino[5,4,3-cd]indole-8-carboxylic acid 2,2-dioxide 856696-05-4P,

1,6-Diethyl-1,3,4,6-tetrahydro-[1,2]thiazepino[5,4,3-cd]indole-8-carboxylic acid 2,2-dioxide
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of tricyclic indole hydroxyethylamine derivs. and their use in treatment of Alzheimer's disease)

RN 856695-82-4 CAPLUS
CN Pyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxylic acid, 1,3,4,6-tetrahydro-1-methyl-, methyl ester, 2,2-dioxide (CA INDEX NAME)



RN 856695-95-9 CAPLUS
CN Pyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxylic acid, 6-ethyl-1,3,4,6-tetrahydro-1-methyl-, methyl ester, 2,2-dioxide (CA INDEX NAME)



RN 856695-96-0 CAPLUS
CN Pyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxylic acid, 6-ethyl-1,3,4,6-tetrahydro-1-methyl-, 2,2-dioxide (CA INDEX NAME)



RN 856696-02-1 CAPLUS
CN Pyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxylic acid, 1,3,4,6-tetrahydro-1-methyl-6-(1-methylethyl)-, 2,2-dioxide (CA INDEX NAME)



RN 856696-03-2 CAPLUS
CN Pyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxylic acid, 1,3,4,6-tetrahydro-1-methyl-6-propyl-, 2,2-dioxide (CA INDEX NAME)



RN 856696-04-3 CAPLUS
CN Pyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxylic acid, 6-butyl-1,3,4,6-tetrahydro-1-methyl-, 2,2-dioxide (CA INDEX NAME)



RN 856696-05-4 CAPLUS
CN Pyrrolo[4,3,2-ef]-2,1-benzothiazepine-8-carboxylic acid, 1,6-diethyl-1,3,4,6-tetrahydro-, 2,2-dioxide (CA INDEX NAME)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:927212 CAPLUS
DOCUMENT NUMBER: 141:395588
TITLE: Preparation of hydroxydiaminopropyl tricyclic indolecarboxamides for treatment of β-amyloid related disease.
INVENTOR(S): Demont, Emmanuel Hubert; Redshaw, Sally; Walter, Daryl Simon
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 74 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004094430	A1	20041104	WO 2004-EP4244	20040421
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004232475	A1	20041104	AU 2004-232475	20040421
CA 2523291	A1	20041104	CA 2004-2523291	20040421
EP 1620438	A1	20060201	EP 2004-728567	20040421
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004009622	A	20060418	BR 2004-9622	20040421
CN 1809573	A	20060726	CN 2004-80017561	20040421
JP 2006524206	T	20061026	JP 2006-505223	20040421
IN 2005DN04531	A	20070817	IN 2005-DN4531	20051006
US 20060229302	A1	20061012	US 2005-553878	20051017
NO 2005005442	A	20051117	NO 2005-5442	20051117
PRIORITY APPLN. INFO.:			GB 2003-9221 A	20030423
			WO 2004-EP4244 W	20040421

OTHER SOURCE(S): MARPAT 141:395588
GI



I

AB Title compds.[I; R1, R2 = alkyl, alkenyl, halo, alkoxy, amino, cyano, OH; m, n = 0-2; p = 1, 2; AB = NR5SO2, NR5CO; R5 = H, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, arylcycloalkyl, heteroarylcycloalkyl; XYZ = NCR8:CR9; R8 = H, alkyl, cycloalkyl; R9 = R8, aryl, heteroaryl, aralkyl, heteroarylalkyl, etc.; R3 = (substituted) alkyl, alkenyl, alkynyl, alkylcycloalkyl, alkylaryl, alkylheteroaryl, alkylheterocyclyl; R4 = H, (substituted) alkyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, heterocyclyl, alkylcycloalkyl, cycloalkylaryl, heterocyclylaryl, etc.], were prepared Thus, 7-ethyl-2-oxo-1,2,3,4-tetrahydro[1,4]diazepino[3,2,1-hi]indole-9-carboxylic acid (preparation given), (2R,3S)-3-amino-1-(3-methoxybenzylamino)-4-phenylbutan-2-ol ditosylate, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, 1-hydroxybenzotriazole hydrate, and 4-ethylmorpholine were stirred 4 h in CH2Cl2/DMF to give 7-ethyl-2-oxo-1,2,3,4-tetrahydro[1,4]diazepino[3,2,1-hi]indole-9-carboxylic acid [(1S,2R)-1-benzyl-2-hydroxy-3-(3-methoxybenzylamino)propyl]amide. I inhibited Asp-2 with IC50 <10 μM.

IT 790252-02-7P 790252-03-8P 790252-04-9P
790252-06-1P 790252-08-3P 790252-10-7P
790252-12-9P 790252-14-1P 790252-16-3P
790252-18-5P 790252-20-9P 790252-22-1P
790252-24-3P 790252-26-5P 790252-28-7P
790252-30-1P 790252-32-3P 790252-34-5P
790252-36-7P 790252-38-9P 790252-40-3P
790252-42-5P 790252-44-7P 790252-46-9P
790252-48-1P 790252-50-5P 790252-52-7P
790252-54-9P 790252-56-1P 790252-58-3P
790252-60-7P 790252-62-9P 790252-64-1P
790252-66-3P 790252-68-5P 790252-70-9P
790252-72-1P 790252-74-3P 790252-75-4P
790252-77-6P 790252-78-7P 790252-79-8P
790252-81-2P 790252-83-4P 790252-85-6P
790252-87-8P 790252-89-0P 790252-91-4P
790252-93-6P 790252-96-9P 790252-99-2P
790253-02-0P 790253-05-3P 790253-08-6P
790253-11-1P 790253-13-3P 790253-15-5P
790253-17-7P 790253-19-9P 790253-21-3P
790253-23-5P 790253-26-8P 790253-29-1P
790253-32-6P 790253-35-9P 790253-37-1P
790253-39-3P 790253-41-7P 790253-43-9P
790253-45-1P 790253-47-3P 790253-49-5P
790253-51-9P 790253-85-9P 790253-87-1P
790253-89-3P 790253-91-7P 790253-93-9P
790253-95-1P 790253-97-3P 790253-99-5P
790254-01-2P 790254-03-4P 790254-05-6P
790254-07-8P 790254-09-0P 790254-11-4P
790254-12-5P 790254-13-6P 790254-15-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of hydroxydiaminopropyl tricyclic indolecarboxamides for treatment of β-amyloid related disease)

RN 790252-02-7 CAPLUS

CN 1H-Pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxamide, 7-ethyl-3,4-dihydro-N-[(1S,2R)-2-hydroxy-3-[[(3-

methoxyphenyl)methyl]amino]-1-(phenylmethyl)propyl]-, 2,2-dioxide (CA INDEX NAME)

Absolute stereochemistry.



RN 790252-03-8 CAPLUS
CN 1H-Pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxamide, 7-ethyl-3,4-dihydro-N-[(1S,2R)-2-hydroxy-3-[[(3-methoxyphenyl)methyl]amino]-1-(phenylmethyl)propyl]-1-methyl-, 2,2-dioxide (CA INDEX NAME)

Absolute stereochemistry.



RN 790252-04-9 CAPLUS
CN 1H-Pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxamide, 7-ethyl-3,4-dihydro-N-[(1S,2R)-2-hydroxy-3-[[(3-methoxyphenyl)methyl]amino]-1-(phenylmethyl)propyl]-1-phenyl-, 2,2-dioxide (CA INDEX NAME)

Absolute stereochemistry.



RN 790252-06-1 CAPLUS
CN Formic acid, compd. with 7-ethyl-3,4-dihydro-N-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[[[3-(trifluoromethyl)phenyl]methyl]amino]propyl]-1-methyl-1H-pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 790252-05-0
CMF C32 H35 F3 N4 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2



RN 790252-08-3 CAPLUS
CN Formic acid, compd. with 7-ethyl-3,4-dihydro-N-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[[[3-(trifluoromethyl)phenyl]methyl]amino]propyl]-1,3-dimethyl-1H-pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 790252-07-2
CMF C33 H37 F3 N4 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

RN 790252-10-7 CAPLUS
CN Formic acid, compd. with N-[(1S,2R)-3-(cyclohexylamino)-2-hydroxy-1-(phenylmethyl)propyl]-7-ethyl-3,4-dihydro-1-methyl-1H-pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 790252-09-4
CMF C30 H40 N4 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 790252-12-9 CAPLUS
CN Formic acid, compd. with N-[(1S,2R)-3-(cyclohexylamino)-2-hydroxy-1-(phenylmethyl)propyl]-7-ethyl-3,4-dihydro-1,3-dimethyl-1H-pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 790252-11-8
CMF C31 H42 N4 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 790252-14-1 CAPLUS
CN Formic acid, compd. with 7-ethyl-3,4-dihydro-N-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[(1,1,5-trimethylhexyl)amino]propyl]-1,3-dimethyl-1H-pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 790252-13-0
CMF C34 H50 N4 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2



RN 790252-16-3 CAPLUS
CN Formic acid, compd. with 7-ethyl-3,4-dihydro-N-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[(1,1,5-trimethylhexyl)amino]propyl]-1-methyl-1H-pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 790252-15-2
CMF C33 H48 N4 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 790252-18-5 CAPLUS
CN Formic acid, compd. with 7-ethyl-3,4-dihydro-N-[(1S,2R)-2-hydroxy-3-[[1-methyl-1-[3-(trifluoromethyl)phenyl]ethyl]amino]-1-(phenylmethyl)propyl]-1-methyl-1H-pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 790252-17-4
CMF C34 H39 F3 N4 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 790252-20-9 CAPLUS
CN Formic acid, compd. with 7-ethyl-3,4-dihydro-N-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[[[3-(trifluoromethyl)phenyl]methyl]amino]propyl]-1-(phenylmethyl)-1H-pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 790252-19-6
CMF C38 H39 F3 N4 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2



RN 790252-22-1 CAPLUS
CN Formic acid, compd. with 7-ethyl-3,4-dihydro-N-[(1S,2R)-2-hydroxy-3-[[1-(3-methoxyphenyl)-1-methylethyl]amino]-1-(phenylmethyl)propyl]-1,3-dimethyl-1H-pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 790252-21-0
CMF C35 H44 N4 O5 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 790252-24-3 CAPLUS
CN Formic acid, compd. with 7-ethyl-3,4-dihydro-N-[(1S,2R)-2-hydroxy-3-[[1-(3-methoxyphenyl)-1-methylethyl]amino]-1-(phenylmethyl)propyl]-1-methyl-1H-pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 790252-23-2
CMF C34 H42 N4 O5 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 790252-26-5 CAPLUS
CN Formic acid, compd. with 7-ethyl-N-[(1S,2R)-3-[[(1-ethyl-1H-pyrazol-4-yl)methyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-3,4-dihydro-1-methyl-1H-pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 790252-25-4
CMF C30 H38 N6 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2



RN 790252-28-7 CAPLUS
CN Formic acid, compd. with 7-ethyl-N-[(1S,2R)-3-[[(1-ethyl-1H-pyrazol-4-yl)methyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-3,4-dihydro-1,3-dimethyl-1H-pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 790252-27-6
CMF C31 H40 N6 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 790252-30-1 CAPLUS
CN Formic acid, compd. with 7-ethyl-3,4-dihydro-N-[(1S,2R)-2-hydroxy-3-[(1-methylethyl)amino]-1-(phenylmethyl)propyl]-1-methyl-1H-pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 790252-29-8
CMF C27 H36 N4 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 790252-32-3 CAPLUS
CN Formic acid, compd. with 7-ethyl-3,4-dihydro-N-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[(tetrahydro-2H-pyran-4-yl)amino]propyl]-1-methyl-1H-pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 790252-31-2
CMF C29 H38 N4 O5 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2



RN 790252-34-5 CAPLUS
CN Formic acid, compd. with N-[(1S,2R)-3-(cyclopropylamino)-2-hydroxy-1-(phenylmethyl)propyl]-7-ethyl-3,4-dihydro-1-methyl-1H-pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 790252-33-4
CMF C27 H34 N4 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 790252-36-7 CAPLUS
CN Formic acid, compd. with 7-ethyl-3,4-dihydro-N-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[(tetrahydro-2H-pyran-4-yl)amino]propyl]-1-(1-methylethyl)-1H-pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 790252-35-6
CMF C31 H42 N4 O5 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 790252-38-9 CAPLUS
CN Formic acid, compd. with 1,7-diethyl-3,4-dihydro-N-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[(tetrahydro-2H-pyran-4-yl)amino]propyl]-1H-pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 790252-37-8
CMF C30 H40 N4 O5 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2



RN 790252-40-3 CAPLUS
CN Formic acid, compd. with 3,4-dihydro-N-[(1S,2R)-2-hydroxy-3-[(1-methylethyl)amino]-1-(phenylmethyl)propyl]-1-methyl-7-(1-methylethyl)-1H-pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 790252-39-0
CMF C28 H38 N4 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 790252-42-5 CAPLUS
CN Formic acid, compd. with N-[(1S,2R)-3-(cyclohexylamino)-2-hydroxy-1-(phenylmethyl)propyl]-3,4-dihydro-1-methyl-7-(1-methylethyl)-1H-pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 790252-41-4
CMF C31 H42 N4 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 790252-44-7 CAPLUS
CN Formic acid, compd. with N-[(1S,2R)-3-(cyclopropylamino)-2-hydroxy-1-(phenylmethyl)propyl]-3,4-dihydro-1-methyl-7-(1-methylethyl)-1H-pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 790252-43-6
CMF C28 H36 N4 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2



RN 790252-46-9 CAPLUS
CN Formic acid, compd. with 3,4-dihydro-N-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[(tetrahydro-2H-pyran-4-yl)amino]propyl]-1-methyl-7-(1-methylethyl)-1H-pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 790252-45-8
CMF C30 H40 N4 O5 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 790252-48-1 CAPLUS
CN Formic acid, compd. with 3,4-dihydro-N-[(1S,2R)-2-hydroxy-3-[[(3-methoxyphenyl)methyl]amino]-1-(phenylmethyl)propyl]-1-methyl-7-(1-methylethyl)-1H-pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 790252-47-0
CMF C33 H40 N4 O5 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 790252-50-5 CAPLUS
CN Formic acid, compd. with N-[(1S,2R)-3-(cyclohexylamino)-2-hydroxy-1-(phenylmethyl)propyl]-1,7-diethyl-3,4-dihydro-1H-pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 790252-49-2
CMF C31 H42 N4 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2



RN 790252-52-7 CAPLUS
CN Formic acid, compd. with 7-ethyl-3,4-dihydro-N-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[(2,2,2-trifluoroethyl)amino]propyl]-1-methyl-1H-pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 790252-51-6
CMF C26 H31 F3 N4 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 790252-54-9 CAPLUS
CN Formic acid, compd. with 7-ethyl-3,4-dihydro-N-[(1S,2R)-2-hydroxy-3-[(2,2,3,3,3-pentafluoropropyl)amino]-1-(phenylmethyl)propyl]-1-methyl-1H-pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 790252-53-8
CMF C27 H31 F5 N4 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 790252-56-1 CAPLUS
CN Formic acid, compd. with N-[(1S,2R)-3-[(cyclopropylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-7-ethyl-3,4-dihydro-1-methyl-1H-pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 790252-55-0
CMF C28 H36 N4 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2



RN 790252-58-3 CAPLUS
CN Formic acid, compd. with N-[(1S,2R)-1-[(3-chlorophenyl)methyl]-3-(cyclopropylamino)-2-hydroxypropyl]-7-ethyl-3,4-dihydro-1-methyl-1H-pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 790252-57-2
CMF C27 H33 Cl N4 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6

CMF C H2 O2

O═CH—OH

RN 790252-60-7 CAPLUS
CN Formic acid, compd. with N-[(1S,2R)-1-[(3-chlorophenyl)methyl]-3-(cyclohexylamino)-2-hydroxypropyl]-7-ethyl-3,4-dihydro-1-methyl-1H-pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 790252-59-4
CMF C30 H39 Cl N4 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 790252-62-9 CAPLUS
CN Formic acid, compd. with N-[(1S,2R)-1-[(3-chlorophenyl)methyl]-2-hydroxy-3-[(tetrahydro-2H-pyran-4-yl)amino]propyl]-7-ethyl-3,4-dihydro-1-methyl-1H-pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 790252-61-8
CMF C29 H37 Cl N4 O5 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

RN 790252-64-1 CAPLUS
CN Formic acid, compd. with N-[(1S,2R)-3-(cyclopropylamino)-1-[(3-fluorophenyl)methyl]-2-hydroxypropyl]-7-ethyl-3,4-dihydro-1-methyl-1H-pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 790252-63-0
CMF C27 H33 F N4 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2



RN 790252-66-3 CAPLUS
CN Formic acid, compd. with 7-ethyl-3,4-dihydro-N-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[(tetrahydro-2H-pyran-4-yl)amino]propyl]-1-(2,2,2-trifluoroethyl)-1H-pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 790252-65-2
CMF C30 H37 F3 N4 O5 S

Absolute stereochemistry.



CM 2

CRN 64-18-6

CMF C H2 O2



RN 790252-68-5 CAPLUS
CN Formic acid, compd. with N-[(1S,2R)-3-(cyclohexylamino)-1-[(3-fluorophenyl)methyl]-2-hydroxypropyl]-7-ethyl-3,4-dihydro-1-methyl-1H-pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 790252-67-4
CMF C30 H39 F N4 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2



RN 790252-70-9 CAPLUS
CN Formic acid, compd. with 7-ethyl-N-[(1S,2R)-1-[(3-fluorophenyl)methyl]-2-hydroxy-3-[(tetrahydro-2H-pyran-4-yl)amino]propyl]-3,4-dihydro-1-methyl-1H-pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 790252-69-6
CMF C29 H37 F N4 O5 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

RN 790252-72-1 CAPLUS
CN Formic acid, compd. with N-[(1S,2R)-3-(cyclohexylamino)-1-[(3,5-difluorophenyl)methyl]-2-hydroxypropyl]-7-ethyl-3,4-dihydro-1-methyl-1H-pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 790252-71-0
CMF C30 H38 F2 N4 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2



RN 790252-74-3 CAPLUS
CN Formic acid, compd. with N-[(1S,2R)-3-(cyclopropylamino)-1-[(3,5-difluorophenyl)methyl]-2-hydroxypropyl]-7-ethyl-3,4-dihydro-1-methyl-1H-pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 790252-73-2
CMF C27 H32 F2 N4 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2



RN 790252-75-4 CAPLUS
CN 1H-Pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxamide, N-[(1S,2R)-3-(cyclobutylamino)-2-hydroxy-1-(phenylmethyl)propyl]-7-ethyl-3,4-dihydro-1-methyl-, 2,2-dioxide (CA INDEX NAME)

Absolute stereochemistry.



RN 790252-77-6 CAPLUS
CN Formic acid, compd. with 7-ethyl-N-[(1S,2R)-3-[(2-fluoroethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-3,4-dihydro-1-methyl-1H-pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 790252-76-5
CMF C26 H33 F N4 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2



RN 790252-78-7 CAPLUS
CN 1H-Pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxamide, 7-ethyl-3,4-dihydro-N-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[(tetrahydro-2,2-dimethyl-2H-pyran-4-yl)amino]propyl]-1-methyl-, 2,2-dioxide (CA INDEX NAME)

Absolute stereochemistry.



RN 790252-79-8 CAPLUS
CN 1H-Pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxamide, N-[(1S,2R)-3-[(1,1-dimethylethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-7-ethyl-3,4-dihydro-1-methyl-, 2,2-dioxide (CA INDEX NAME)

Absolute stereochemistry.



RN 790252-81-2 CAPLUS
CN Formic acid, compd. with 3,4-dihydro-N-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[[[3-(trifluoromethyl)phenyl]methyl]amino]propyl]-1-methyl-7-propyl-1H-pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 790252-80-1
CMF C33 H37 F3 N4 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2



RN 790252-83-4 CAPLUS
CN Formic acid, compd. with N-[(1S,2R)-3-(cyclohexylamino)-2-hydroxy-1-(phenylmethyl)propyl]-3,4-dihydro-1-methyl-7-propyl-1H-pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 790252-82-3
CMF C31 H42 N4 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

RN 790252-85-6 CAPLUS
CN Formic acid, compd. with 3,4-dihydro-N-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[(tetrahydro-2H-pyran-4-yl)amino]propyl]-1-methyl-7-propyl-1H-pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 790252-84-5
CMF C30 H40 N4 O5 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2



RN 790252-87-8 CAPLUS
CN Formic acid, compd. with N-[(1S,2R)-3-[[(1-ethyl-1H-pyrazol-4-yl)methyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-3,4-dihydro-1-methyl-7-propyl-1H-pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 790252-86-7
CMF C31 H40 N6 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2



RN 790252-89-0 CAPLUS
CN Formic acid, compd. with 1-ethyl-3,4-dihydro-N-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[[[3-(trifluoromethyl)phenyl]methyl]amino]propyl]-7-propyl-1H-pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 790252-88-9
CMF C34 H39 F3 N4 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 790252-91-4 CAPLUS
CN Formic acid, compd. with N-[(1S,2R)-3-(cyclohexylamino)-2-hydroxy-1-(phenylmethyl)propyl]-1-ethyl-3,4-dihydro-7-propyl-1H-pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 790252-90-3
CMF C32 H44 N4 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 790252-93-6 CAPLUS
CN Formic acid, compd. with 1-ethyl-3,4-dihydro-N-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[(tetrahydro-2H-pyran-4-yl)amino]propyl]-7-propyl-1H-pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 790252-92-5
CMF C31 H42 N4 O5 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2



RN 790252-96-9 CAPLUS
CN Formic acid, compd. with 1-ethyl-N-[(1S,2R)-3-[[(1-ethyl-1H-pyrazol-4-yl)methyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-3,4-dihydro-7-propyl-1H-pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 790252-95-8
CMF C32 H42 N6 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 790252-99-2 CAPLUS
CN Formic acid, compd. with N-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[(tetrahydro-2H-pyran-4-yl)amino]propyl]-7-ethyl-3,4-dihydro-1-methyl-1H-pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 790252-98-1
CMF C29 H36 F2 N4 O5 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 790253-02-0 CAPLUS
CN Formic acid, compd. with 7-ethyl-3,4-dihydro-N-[(1S,2R)-2-hydroxy-3-[(2-methoxyethyl)amino]-1-(phenylmethyl)propyl]-1-methyl-1H-pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 790253-01-9
CMF C27 H36 N4 O5 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2



RN 790253-05-3 CAPLUS
CN Formic acid, compd. with 7-ethyl-N-[(1S,2R)-3-(ethylamino)-2-hydroxy-1-(phenylmethyl)propyl]-3,4-dihydro-1-methyl-1H-pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 790253-04-2
CMF C26 H34 N4 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 790253-08-6 CAPLUS
CN Formic acid, compd. with 7-ethyl-3,4-dihydro-N-[(1S,2R)-2-hydroxy-3-[[(1S)-1-methylpropyl]amino]-1-(phenylmethyl)propyl]-1-methyl-1H-pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 790253-07-5
CMF C28 H38 N4 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 790253-11-1 CAPLUS
CN Formic acid, compd. with N-[(1S,2R)-3-(butylamino)-2-hydroxy-1-(phenylmethyl)propyl]-7-ethyl-3,4-dihydro-1-methyl-1H-pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 790253-10-0
CMF C28 H38 N4 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2



RN 790253-13-3 CAPLUS
CN 1H-Pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxamide, 7-ethyl-3,4-dihydro-N-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-(2-propyn-1-ylamino)propyl]-1-methyl-, 2,2-dioxide (CA INDEX NAME)

Absolute stereochemistry.



RN 790253-15-5 CAPLUS
CN 1H-Pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxamide, N-[(1S,2R)-3-(cyclopentylamino)-2-hydroxy-1-(phenylmethyl)propyl]-7-ethyl-3,4-dihydro-1-methyl-, 2,2-dioxide (CA INDEX NAME)

Absolute stereochemistry.



RN 790253-17-7 CAPLUS
CN 1H-Pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxamide, 7-ethyl-3,4-dihydro-N-[(1S,2R)-2-hydroxy-3-[(2-methylpropyl)amino]-1-(phenylmethyl)propyl]-1-methyl-, 2,2-dioxide (CA INDEX NAME)

Absolute stereochemistry.



RN 790253-19-9 CAPLUS
CN 1H-Pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxamide, 7-ethyl-3,4-dihydro-N-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-(propylamino)propyl]-1-methyl-, 2,2-dioxide (CA INDEX NAME)

Absolute stereochemistry.



RN 790253-21-3 CAPLUS
CN 1H-Pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxamide, 7-ethyl-3,4-dihydro-N-[(1S,2R)-2-hydroxy-3-[[(1R)-1-methylpropyl]amino]-1-

(phenylmethyl)propyl]-1-methyl-, 2,2-dioxide (CA INDEX NAME)

Absolute stereochemistry.



RN 790253-23-5 CAPLUS
CN 1H-Pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxamide, N-[(1S,2R)-3-[(2,2-difluoroethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-7-ethyl-3,4-dihydro-1-methyl-, 2,2-dioxide (CA INDEX NAME)

Absolute stereochemistry.



RN 790253-26-8 CAPLUS
CN Formic acid, compd. with 7-ethyl-3,4-dihydro-N-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[(phenylmethyl)amino]propyl]-1-methyl-1H-pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 790253-25-7
CMF C31 H36 N4 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2



RN 790253-29-1 CAPLUS
CN Formic acid, compd. with 7-ethyl-3,4-dihydro-N-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[(2-pyridinylmethyl)amino]propyl]-1-methyl-1H-pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 790253-28-0
CMF C30 H35 N5 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 790253-32-6 CAPLUS
CN Formic acid, compd. with 7-ethyl-3,4-dihydro-N-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[(4-pyridinylmethyl)amino]propyl]-1-methyl-1H-pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 790253-31-5
CMF C30 H35 N5 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 790253-35-9 CAPLUS
CN Formic acid, compd. with 7-ethyl-3,4-dihydro-N-[(1S,2R)-2-hydroxy-3-[(2-phenylethyl)amino]-1-(phenylmethyl)propyl]-1-methyl-1H-pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 790253-34-8
CMF C32 H38 N4 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2



RN 790253-37-1 CAPLUS
CN Formic acid, compd. with 7-ethyl-3,4-dihydro-N-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[[[3-(trifluoromethoxy)phenyl]methyl]amino]propyl]-1-methyl-1H-pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 790253-36-0
CMF C32 H35 F3 N4 O5 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 790253-39-3 CAPLUS
CN Formic acid, compd. with 7-ethyl-3,4-dihydro-N-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[(3-pyridinylmethyl)amino]propyl]-1-methyl-1H-pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 790253-38-2
CMF C30 H35 N5 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 790253-41-7 CAPLUS
CN Formic acid, compd. with 7-ethyl-3,4-dihydro-N-[(1S,2R)-2-hydroxy-3-[[(2-methylphenyl)methyl]amino]-1-(phenylmethyl)propyl]-1-methyl-1H-pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 790253-40-6
CMF C32 H38 N4 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2



RN 790253-43-9 CAPLUS
CN Formic acid, compd. with 7-ethyl-3,4-dihydro-N-[(1S,2R)-2-hydroxy-3-[[(3-methylphenyl)methyl]amino]-1-(phenylmethyl)propyl]-1-methyl-1H-pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 790253-42-8
CMF C32 H38 N4 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 790253-45-1 CAPLUS
CN Formic acid, compd. with 7-ethyl-3,4-dihydro-N-[(1S,2R)-2-hydroxy-3-[[(4-methylphenyl)methyl]amino]-1-(phenylmethyl)propyl]-1-methyl-1H-pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 790253-44-0
CMF C32 H38 N4 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 790253-47-3 CAPLUS
CN Formic acid, compd. with N-[(1S,2R)-3-[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-7-ethyl-3,4-dihydro-1-methyl-1H-pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 790253-46-2
CMF C33 H38 N4 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2



RN 790253-49-5 CAPLUS
CN Formic acid, compd. with 1,1-dimethylethyl 7-ethyl-3,4-dihydro-9-[[[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[[[3-(trifluoromethyl)phenyl]methyl]amino]propyl]amino]carbonyl]-1H-pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-1-acetate 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 790253-48-4
CMF C37 H43 F3 N4 O6 S

Absolute stereochemistry.



CM 2

CRN 64-18-6

CMF C H2 O2



RN 790253-51-9 CAPLUS
CN Formic acid, compd. with 7-ethyl-3,4-dihydro-N-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[[[1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl]methyl]amino]propyl]-1-methyl-1H-pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 790253-50-8
CMF C30 H35 F3 N6 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2



RN 790253-85-9 CAPLUS
CN 1H-Pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxamide, N-[(1S,2R)-3-amino-2-hydroxy-1-(phenylmethyl)propyl]-7-ethyl-3,4-dihydro-1-methyl-, 2,2-dioxide (CA INDEX NAME)

Absolute stereochemistry.



RN 790253-87-1 CAPLUS
CN Formic acid, compd. with 7-ethyl-3,4-dihydro-N-[(1S,2R)-2-hydroxy-3-(methylamino)-1-(phenylmethyl)propyl]-1-methyl-1H-pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 790253-86-0
CMF C25 H32 N4 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2



RN 790253-89-3 CAPLUS
CN Formic acid, compd. with 3,4-dihydro-N-[(1S,2R)-2-hydroxy-3-(methylamino)-1-(phenylmethyl)propyl]-1-methyl-7-(1-methylethyl)-1H-pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 790253-88-2

CMF C26 H34 N4 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2



RN 790253-91-7 CAPLUS
CN Formic acid, compd. with N-[(1S,2R)-1-[(3-chlorophenyl)methyl]-2-hydroxy-3-(methylamino)propyl]-7-ethyl-3,4-dihydro-1-methyl-1H-pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 790253-90-6
CMF C25 H31 Cl N4 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2



RN 790253-93-9 CAPLUS
CN Formic acid, compd. with 7-ethyl-N-[(1S,2R)-1-[(3-fluorophenyl)methyl]-2-hydroxy-3-(methylamino)propyl]-3,4-dihydro-1-methyl-1H-pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 790253-92-8
CMF C25 H31 F N4 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2



RN 790253-95-1 CAPLUS
CN 1H-Pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-1-acetic acid, 7-ethyl-3,4-dihydro-9-[[[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[[[3-(trifluoromethyl)phenyl]methyl]amino]propyl]amino]carbonyl]-, 2,2-dioxide (CA INDEX NAME)

Absolute stereochemistry.



RN 790253-97-3 CAPLUS
CN Formic acid, compd. with N-[(1S,2R)-3-[[(6-bromo-2-pyridinyl)methyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-7-ethyl-3,4-dihydro-1-methyl-1H-pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 790253-96-2
CMF C30 H34 Br N5 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2



RN 790253-99-5 CAPLUS
CN Formic acid, compd. with 7-ethyl-3,4-dihydro-N-[(1S,2R)-2-hydroxy-3-[[[5-[(methylamino)carbonyl]-3-pyridinyl]methyl]amino]-1-(phenylmethyl)propyl]-1-methyl-1H-pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 790253-98-4
CMF C32 H38 N6 O5 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2



RN 790254-01-2 CAPLUS
CN Formic acid, compd. with N-[(1S,2R)-3-[([2,2'-bipyridin]-6-ylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-7-ethyl-3,4-dihydro-1-methyl-1H-pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 790254-00-1
CMF C35 H38 N6 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2



RN 790254-03-4 CAPLUS
CN Formic acid, compd. with 7-ethyl-3,4-dihydro-N-[(1S,2R)-2-hydroxy-3-[[(6-methyl-2-quinoxalinyl)methyl]amino]-1-(phenylmethyl)propyl]-1-methyl-1H-pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxamide 2,2-dioxide (1:1)
(CA INDEX NAME)

CM 1

CRN 790254-02-3
CMF C34 H38 N6 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6

CMF C H2 O2

RN 790254-05-6 CAPLUS
CN Formic acid, compd. with 7-ethyl-3,4-dihydro-N-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[(3-quinolinylmethyl)amino]propyl]-1-methyl-1H-pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 790254-04-5
CMF C34 H37 N5 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

RN 790254-07-8 CAPLUS
CN Formic acid, compd. with 7-ethyl-3,4-dihydro-N-[(1S,2R)-2-hydroxy-3-[[(6-methyl-2-pyridinyl)methyl]amino]-1-(phenylmethyl)propyl]-1-methyl-1H-pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 790254-06-7
CMF C31 H37 N5 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2



RN 790254-09-0 CAPLUS
CN Formic acid, compd. with 7-ethyl-N-[(1S,2R)-3-[[(5-ethyl-2-thienyl)methyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-3,4-dihydro-1-methyl-1H-pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 790254-08-9
CMF C31 H38 N4 O4 S2

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 790254-11-4 CAPLUS
CN Formic acid, compd. with 7-ethyl-3,4-dihydro-N-[(1S,2R)-2-hydroxy-3-[[(5-methyl-2-pyrazinyl)methyl]amino]-1-(phenylmethyl)propyl]-1-methyl-1H-pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 790254-10-3
CMF C30 H36 N6 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 790254-12-5 CAPLUS
CN 1H-Pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxamide, 7-ethyl-N-[(1S,2R)-3-[[(3-ethyl-5-isoxazolyl)methyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-3,4-dihydro-1-methyl-, 2,2-dioxide (CA INDEX NAME)

Absolute stereochemistry.



RN 790254-13-6 CAPLUS
CN 1H-Pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxamide, N-[(1S,2R)-3-[[(1S)-2-(cyclohexylamino)-1-methyl-2-oxoethyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-7-ethyl-3,4-dihydro-1-methyl-, 2,2-dioxide (CA INDEX NAME)

Absolute stereochemistry.



RN 790254-15-8 CAPLUS
CN Formic acid, compd. with N-[(1S,2R)-3-[(4,4-difluorocyclohexyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-7-ethyl-3,4-dihydro-1-methyl-1H-pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxamide 2,2-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 790254-14-7
CMF C30 H38 F2 N4 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2



IT 790255-60-6 790255-61-7 790255-62-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of hydroxydiaminopropyl tricyclic indolecarboxamides for treatment of β-amyloid related disease)
RN 790255-60-6 CAPLUS
CN Carbamic acid, [(2R,3S)-3-[[(7-ethyl-3,4-dihydro-1-methyl-2,2-dioxido-1H-pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepin-9-yl)carbonyl]amino]-2-hydroxy-4-phenylbutyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 790255-61-7 CAPLUS
CN Carbamic acid, [(2R,3S)-3-[[(7-ethyl-3,4-dihydro-1-methyl-2,2-dioxido-1H-pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepin-9-yl)carbonyl]amino]-2-hydroxy-4-phenylbutyl]methyl-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 790255-62-8 CAPLUS
CN Carbamic acid, [(2R,3S)-3-[[[3,4-dihydro-1-methyl-7-(1-methylethyl)-2,2-dioxido-1H-pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepin-9-yl]carbonyl]amino]-2-hydroxy-4-phenylbutyl]methyl-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 790254-27-2P 790254-28-3P 790254-29-4P
790254-30-7P 790254-39-6P 790254-40-9P
790254-42-1P 790254-43-2P 790254-44-3P
790254-45-4P 790254-46-5P 790254-47-6P
790254-48-7P 790254-49-8P 790254-53-4P
790254-55-6P 790254-56-7P 790254-63-6P,
7-Ethyl-3,4-dihydro-1H-[1,2,5]thiadiazepino[3,4,5-hi]indole-9-carboxylic acid 2,2-dioxide 790254-64-7P,
7-Ethyl-1-methyl-3,4-dihydro-1H-[1,2,5]thiadiazepino[3,4,5-hi]indole-9-carboxylic acid 2,2-dioxide 790254-65-8P,
7-Ethyl-1-phenyl-3,4-dihydro-1H-[1,2,5]thiadiazepino[3,4,5-hi]indole-9-carboxylic acid 2,2-dioxide 790254-67-0P,
7-Ethyl-1,3-dimethyl-3,4-dihydro-1H-[1,2,5]thiadiazepino[3,4,5-hi]indole-9-carboxylic acid 2,2-dioxide 790254-68-1P,
7-Ethyl-1-(phenylmethyl)-3,4-dihydro-1H-[1,2,5]thiadiazepino[3,4,5-hi]indole-9-carboxylic acid 2,2-dioxide 790254-70-5P,
7-Ethyl-1-(1-methylethyl)-3,4-dihydro-1H-[1,2,5]thiadiazepino[3,4,5-hi]indole-9-carboxylic acid 2,2-dioxide 790254-71-6P,
1,7-Diethyl-3,4-dihydro-1H-[1,2,5]thiadiazepino[3,4,5-hi]indole-9-carboxylic acid 2,2-dioxide 790254-73-8P,
1-Methyl-7-(1-methylethyl)-3,4-dihydro-1H-[1,2,5]thiadiazepino[3,4,5-hi]indole-9-carboxylic acid 2,2-dioxide 790254-74-9P,
7-Ethyl-1-(2,2,2-trifluoroethyl)-3,4-dihydro-1H-[1,2,5]thiadiazepino[3,4,5-

hi]indole-9-carboxylic acid 2,2-dioxide 790254-75-0P,
1-Methyl-7-propyl-3,4-dihydro-1H-[1,2,5]thiadiazepino[3,4,5-hi]indole-9-carboxylic acid 2,2-dioxide 790254-78-3P,
1-Ethyl-7-propyl-3,4-dihydro-1H-[1,2,5]thiadiazepino[3,4,5-hi]indole-9-carboxylic acid 2,2-dioxide 790254-79-4P,
1-[2-[(1,1-Dimethylethyl)oxy]-2-oxoethyl]-7-ethyl-3,4-dihydro-1H-[1,2,5]thiadiazepino[3,4,5-hi]indole-9-carboxylic acid 2,2-dioxide
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of hydroxydiaminopropyl tricyclic indolecarboxamides for treatment of β-amyloid related disease)

RN 790254-27-2 CAPLUS
CN 1H-Pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxylic acid, 3,4-dihydro-7-propyl-, methyl ester, 2,2-dioxide (CA INDEX NAME)



RN 790254-28-3 CAPLUS
CN 1H-Pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxylic acid, 3,4-dihydro-7-(1-methylethyl)-, methyl ester, 2,2-dioxide (CA INDEX NAME)



RN 790254-29-4 CAPLUS
CN Carbamic acid, [(2R,3S)-4-(3-chlorophenyl)-3-[[(7-ethyl-3,4-dihydro-1-methyl-2,2-dioxido-1H-pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepin-9-yl)carbonyl]amino]-2-hydroxybutyl]methyl-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 790254-30-7 CAPLUS
CN Carbamic acid, [(2R,3S)-3-[[(7-ethyl-3,4-dihydro-1-methyl-2,2-dioxido-1H-pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepin-9-yl)carbonyl]amino]-4-(3-fluorophenyl)-2-hydroxybutyl]methyl-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 790254-39-6 CAPLUS
CN 1H-Pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxylic acid, 7-ethyl-3,4-dihydro-, methyl ester, 2,2-dioxide (CA INDEX NAME)



RN 790254-40-9 CAPLUS
CN 1H-Pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxylic acid, 7-ethyl-3,4-dihydro-1-methyl-, methyl ester, 2,2-dioxide (CA INDEX NAME)



RN 790254-42-1 CAPLUS
CN 1H-Pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxylic acid, 7-ethyl-3,4-dihydro-1-phenyl-, methyl ester, 2,2-dioxide (CA INDEX NAME)



RN 790254-43-2 CAPLUS
CN 1H-Pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxylic acid, 3,4-dihydro-1-methyl-7-(1-methylethyl)-, methyl ester, 2,2-dioxide (CA INDEX NAME)



RN 790254-44-3 CAPLUS
CN 1H-Pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxylic acid, 3,4-dihydro-1-methyl-7-propyl-, methyl ester, 2,2-dioxide (CA INDEX NAME)



RN 790254-45-4 CAPLUS
CN 1H-Pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxylic acid, 7-ethyl-3,4-dihydro-1-(1-methylethyl)-, methyl ester, 2,2-dioxide (CA INDEX NAME)



RN 790254-46-5 CAPLUS
CN 1H-Pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxylic acid, 1,7-diethyl-3,4-dihydro-, methyl ester, 2,2-dioxide (CA INDEX NAME)



RN 790254-47-6 CAPLUS
CN 1H-Pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxylic acid, 7-ethyl-3,4-dihydro-1-(2,2,2-trifluoroethyl)-, methyl ester, 2,2-dioxide (CA INDEX NAME)



RN 790254-48-7 CAPLUS
CN 1H-Pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxylic acid, 1-ethyl-3,4-dihydro-7-propyl-, methyl ester, 2,2-dioxide (CA INDEX NAME)



RN 790254-49-8 CAPLUS
CN 1H-Pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-1-acetic acid, 7-ethyl-3,4-dihydro-9-(methoxycarbonyl)-, 1,1-dimethylethyl ester, 2,2-dioxide (CA INDEX NAME)



RN 790254-53-4 CAPLUS
CN 1H-Pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxylic acid, 7-ethyl-3,4-dihydro-, ethyl ester, 2,2-dioxide (CA INDEX NAME)



RN 790254-55-6 CAPLUS
CN 1H-Pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxylic acid, 7-ethyl-3,4-dihydro-1-methyl-, ethyl ester, 2,2-dioxide (CA INDEX NAME)



RN 790254-56-7 CAPLUS
CN 1H-Pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxylic acid, 7-ethyl-3,4-dihydro-1-phenyl-, ethyl ester, 2,2-dioxide (CA INDEX NAME)



RN 790254-63-6 CAPLUS
CN 1H-Pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxylic acid, 7-ethyl-3,4-dihydro-, 2,2-dioxide (CA INDEX NAME)



RN 790254-64-7 CAPLUS
CN 1H-Pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxylic acid, 7-ethyl-3,4-dihydro-1-methyl-, 2,2-dioxide (CA INDEX NAME)



RN 790254-65-8 CAPLUS
CN 1H-Pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxylic acid, 7-ethyl-3,4-dihydro-1-phenyl-, 2,2-dioxide (CA INDEX NAME)



RN 790254-67-0 CAPLUS
CN 1H-Pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxylic acid, 7-ethyl-3,4-dihydro-1,3-dimethyl-, 2,2-dioxide (CA INDEX NAME)



RN 790254-68-1 CAPLUS
CN 1H-Pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxylic acid, 7-ethyl-3,4-dihydro-1-(phenylmethyl)-, 2,2-dioxide (CA INDEX NAME)



RN 790254-70-5 CAPLUS
CN 1H-Pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxylic acid, 7-ethyl-3,4-dihydro-1-(1-methylethyl)-, 2,2-dioxide (CA INDEX NAME)



RN 790254-71-6 CAPLUS
CN 1H-Pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxylic acid, 1,7-diethyl-3,4-dihydro-, 2,2-dioxide (CA INDEX NAME)



RN 790254-73-8 CAPLUS
CN 1H-Pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxylic acid, 3,4-dihydro-1-methyl-7-(1-methylethyl)-, 2,2-dioxide (CA INDEX NAME)



RN 790254-74-9 CAPLUS
CN 1H-Pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxylic acid, 7-ethyl-3,4-dihydro-1-(2,2,2-trifluoroethyl)-, 2,2-dioxide (CA INDEX NAME)



RN 790254-75-0 CAPLUS
CN 1H-Pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxylic acid, 3,4-dihydro-1-methyl-7-propyl-, 2,2-dioxide (CA INDEX NAME)



RN 790254-78-3 CAPLUS
CN 1H-Pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxylic acid, 1-ethyl-3,4-dihydro-7-propyl-, 2,2-dioxide (CA INDEX NAME)



RN 790254-79-4 CAPLUS
CN 1H-Pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-1-acetic acid, 9-carboxy-7-ethyl-3,4-dihydro-, 1-(1,1-dimethylethyl) ester, 2,2-dioxide (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:679911 CAPLUS
DOCUMENT NUMBER: 141:374641
TITLE: Behavioural effects of thieno and pyrazolo[2,1]benzothiazepine derivatives in mice
AUTHOR(S): Exposito-Orta, Maria A.; Albertos, Luz M.; Darias, Victoriano; Sanchez-Mateo, Candelaria C.
CORPORATE SOURCE: Departamento de Farmacologia, Facultad de Farmacia, Universidad de La Laguna, La Laguna, Tenerife, Spain
SOURCE: Arzneimittel Forschung (2004), 54(7), 365-370
CODEN: ARZNAD; ISSN: 0004-4172
PUBLISHER: Editio Cantor Verlag
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Behavioral studies were conducted in mice with a number of hetero[2,1]benzothiazepine derivs., analogs of tianeptine. Previously published studies in mice have shown that some of these compds. were effective in the tetrabenazine and Porsolt tests. In the present study, four of the 15 compds. under study potentiated the actions of 5-hydroxytryptophan (5-HTP, 50 mg/kg i.p.), but no significant antagonism of the apomorphine (16 mg/kg s.c.)-induced hypothermia and potentiation of the amphetamine actions was found. Moreover, some of them inhibited the stereotyped behavior and/or climbing behavior of low doses of apomorphine and compound 2 was effective in the plus-maze test. These compds. also produced a slight inhibition of exploratory behavior in the holeboard test. On the other hand, no significant muscle relaxant and anticonvulsant activities were observed at any dose employed. Together, these data suggest that some of the compds. under study combine the antidepressant effects with addnl. neuroleptic or anxiolytic activities in mice.
IT 150555-76-3 150555-77-4 253177-70-7
253177-71-8 253177-72-9 253177-76-3
253177-77-4 253177-78-5 253177-79-6
286854-11-3
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(behavioral effects of thieno and pyrazolo[2,1]benzothiazepine derivs. in mice)
RN 150555-76-3 CAPLUS
CN 2H-Pyrazolo[3,4-c][2,1]benzothiazepine, 4,9-dihydro-2,9-dimethyl-4-[2-(1-pyrrolidinyl)ethoxy]-, 10,10-dioxide (CA INDEX NAME)



RN 150555-77-4 CAPLUS
CN Ethanamine, 2-[(5,10-dihydro-5-methyl-4,4-dioxidothieno[3,4-c][2,1]benzothiazepin-10-yl)oxy]-N-methyl- (CA INDEX NAME)



RN 253177-70-7 CAPLUS
CN Ethanamine, 2-[(5,10-dihydro-5-methyl-4,4-dioxidothieno[3,4-c][2,1]benzothiazepin-10-yl)oxy]-N,N-dimethyl- (CA INDEX NAME)



RN 253177-71-8 CAPLUS
CN Thieno[3,4-c][2,1]benzothiazepine,

5,10-dihydro-5-methyl-10-[2-(1-pyrrolidinyl)ethoxy]-, 4,4-dioxide (CA INDEX NAME)



RN 253177-72-9 CAPLUS
CN Thieno[3,4-c][2,1]benzothiazepine, 5,10-dihydro-5-methyl-10-[2-(1-piperazinyl)ethoxy]-, 4,4-dioxide (CA INDEX NAME)



RN 253177-76-3 CAPLUS
CN Ethanamine, 2-[(4,9-dihydro-2,9-dimethyl-10,10-dioxido-2H-pyrazolo[3,4-c][2,1]benzothiazepin-4-yl)oxy]-N-methyl- (CA INDEX NAME)



RN 253177-77-4 CAPLUS
CN Ethanamine, 2-[(4,9-dihydro-2,9-dimethyl-10,10-dioxido-2H-pyrazolo[3,4-c][2,1]benzothiazepin-4-yl)oxy]-N,N-dimethyl- (CA INDEX NAME)



RN 253177-78-5 CAPLUS
CN 2H-Pyrazolo[3,4-c][2,1]benzothiazepine, 4,9-dihydro-2,9-dimethyl-4-[2-(1-piperidinyl)ethoxy]-, 10,10-dioxide (CA INDEX NAME)



RN 253177-79-6 CAPLUS
CN 2H-Pyrazolo[3,4-c][2,1]benzothiazepine, 4,9-dihydro-2,9-dimethyl-4-[2-(1-piperazinyl)ethoxy]-, 10,10-dioxide (CA INDEX NAME)



RN 286854-11-3 CAPLUS
CN Thieno[3,4-c][2,1]benzothiazepine, 5,10-dihydro-5-methyl-10-[2-(1-piperidinyl)ethoxy]-, 4,4-dioxide (CA INDEX NAME)



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 7 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:126817 CAPLUS
DOCUMENT NUMBER: 139:332861
TITLE: Neuropharmacological study of hetero[2,1]benzothiazepine derivatives analogues of tianeptine
AUTHOR(S): Sanchez-Mateo, Candelaria C.; Darias, Victoriano; Exposito-Orta, M. Auxiliadora; Albertos, Luz M.
CORPORATE SOURCE: Facultad de Farmacia, Departamento de Farmacologia, Universidad de La Laguna, Tenerife, 38071, Spain
SOURCE: Farmaco (2003), 58(1), 1-10
CODEN: FRMCE8; ISSN: 0014-827X
PUBLISHER: Editions Scientifiques et Medicales Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Neuropharmacol. studies were conducted in mice with a number of hetero[2,1]benzothiazepine derivs., analogs of tianeptine. Seven of the 12 compds. under study potentiated the actions of 5-hydroxytryptophan (5-HTP, 50 mg/kg i.p.) and/or antagonized the hypothermia induced by high doses of apomorphine. Moreover, some of them inhibited the head twitches induced by 5-HTP (250 mg/kg i.p.) and the stereotyped behavior and/or climbing behavior of low doses of apomorphine. These compds. also produced a slight inhibition of exploratory behavior in the holeboard test. On the other hand, no significant muscle relaxant, anticonvulsant and anxiolytic activities were observed at any dose employed. Together, these data suggest that some of the compds. under study exert antidepressant and neuroleptic effects in mice with no muscle relaxant, anxiolytic and anticonvulsant activities.

IT 150555-79-6 616228-16-1 616228-17-2
616228-18-3 616228-19-4 616228-23-0
616228-24-1 616228-25-2 616228-26-3
616228-27-4 616228-28-5 616228-29-6
616228-34-3 616228-35-4 616228-36-5
616228-37-6
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(neuropharmacol. study of hetero[2,1]benzothiazepine derivs. analogs of tianeptine)

RN 150555-79-6 CAPLUS
CN 2H-Pyrazolo[3,4-c][2,1]benzothiazepin-4(9H)-one, 2,9-dimethyl-, O-[2-(dimethylamino)ethyl]oxime, 10,10-dioxide, (4Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 616228-16-1 CAPLUS
CN Thieno[3,4-c][2,1]benzothiazepin-10(5H)-one, 5-methyl-,
O-[2-(dimethylamino)ethyl]oxime 4,4-dioxide, (10Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 616228-17-2 CAPLUS
CN Thieno[3,4-c][2,1]benzothiazepin-10(5H)-one, 5-methyl-,
O-[2-(1-pyrrolidinyl)ethyl]oxime 4,4-dioxide, (10Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 616228-18-3 CAPLUS
CN Thieno[3,4-c][2,1]benzothiazepin-10(5H)-one, 5-methyl-,
O-[2-(1-piperidinyl)ethyl]oxime 4,4-dioxide, (10Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 616228-19-4 CAPLUS
CN Thieno[3,4-c][2,1]benzothiazepin-10(5H)-one, 5-methyl-,
O-[2-(4-morpholinyl)ethyl]oxime 4,4-dioxide, (10Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 616228-23-0 CAPLUS
CN 2H-Pyrazolo[3,4-c][2,1]benzothiazepin-4(9H)-one, 2,9-dimethyl-,
O-[2-(1-pyrrolidinyl)ethyl]oxime 10,10-dioxide, (4Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 616228-24-1 CAPLUS
CN 2H-Pyrazolo[3,4-c][2,1]benzothiazepin-4(9H)-one, 2,9-dimethyl-,
O-[2-(1-piperidinyl)ethyl]oxime 10,10-dioxide, (4Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 616228-25-2 CAPLUS
CN 2H-Pyrazolo[3,4-c][2,1]benzothiazepin-4(9H)-one, 2,9-dimethyl-, O-[2-(4-morpholinyl)ethyl]oxime 10,10-dioxide, (4Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 616228-26-3 CAPLUS
CN Thieno[3,4-c][2,1]benzothiazepin-10(5H)-one, 5-methyl-, O-[2-(dimethylamino)ethyl]oxime 4,4-dioxide, (10E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 616228-27-4 CAPLUS
CN Thieno[3,4-c][2,1]benzothiazepin-10(5H)-one, 5-methyl-, O-[2-(1-pyrrolidinyl)ethyl]oxime 4,4-dioxide, (10E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 616228-28-5 CAPLUS
CN Thieno[3,4-c][2,1]benzothiazepin-10(5H)-one, 5-methyl-,
O-[2-(1-piperidinyl)ethyl]oxime 4,4-dioxide, (10E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 616228-29-6 CAPLUS
CN Thieno[3,4-c][2,1]benzothiazepin-10(5H)-one, 5-methyl-,
O-[2-(4-morpholinyl)ethyl]oxime 4,4-dioxide, (10E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 616228-34-3 CAPLUS
CN 2H-Pyrazolo[3,4-c][2,1]benzothiazepin-4(9H)-one, 2,9-dimethyl-,
O-[2-(dimethylamino)ethyl]oxime 10,10-dioxide, (4E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 616228-35-4 CAPLUS
CN 2H-Pyrazolo[3,4-c][2,1]benzothiazepin-4(9H)-one, 2,9-dimethyl-, O-[2-(1-pyrrolidinyl)ethyl]oxime 10,10-dioxide, (4E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 616228-36-5 CAPLUS
CN 2H-Pyrazolo[3,4-c][2,1]benzothiazepin-4(9H)-one, 2,9-dimethyl-, O-[2-(1-piperidinyl)ethyl]oxime 10,10-dioxide, (4E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 616228-37-6 CAPLUS
CN 2H-Pyrazolo[3,4-c][2,1]benzothiazepin-4(9H)-one, 2,9-dimethyl-, O-[2-(4-morpholinyl)ethyl]oxime 10,10-dioxide, (4E)- (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:116497 CAPLUS
DOCUMENT NUMBER: 139:159790
TITLE: Psychopharmacological effects of tianeptine analogous hetero[2,1]benzothiazepine derivatives
AUTHOR(S): Sanchez-Mateo, Candelaria C.; Darias, Victoriano; Albertos, Luz M.; Exposito-Orta, Maria A.
CORPORATE SOURCE: Departamento de Farmacologia, Facultad de Farmacia, Universidad de La Laguna, La Laguna, Spain
SOURCE: Arzneimittel-Forschung (2003), 53(1), 12-20
CODEN: ARZNAD; ISSN: 0004-4172
PUBLISHER: Editio Cantor Verlag
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The psychopharmacol. effects of a number of thieno and pyrazolo[2,1]benzothiazepine derivs. as well as several synthetic intermediate compds. were investigated in mice. Previously published studies in mice have shown that some of these compds. were effective in the tetrabenazine and Porsolt tests. In the present study, 7 of the 15 compds. under study clearly antagonized the apomorphine (16 mg/kg s.c.)-induced hypothermia, but no significant potentiation of the 5-hydroxytryptophan (5-HTP) and amphetamine actions was found. Five of them inhibited the syndrome induced by 5-HTP (250 mg/kg i.p.). Moreover, some of them were effective in the plus-maze test and antagonized the apomorphine (3 mg/kg s.c.)-induced effects. These compds. produced a moderate inhibition of exploratory behavior in the holeboard test, but they had no significant muscle relaxant and anticonvulsant activities. The results indicate that some of the compds. under study combine a spectrum of antidepressant, anxiolytic and neuroleptic properties in mice with a lack of muscle relaxant and anticonvulsant activities.
IT 153757-46-1 155144-46-0 155144-49-3
198212-74-7 198212-80-5 198212-84-9
204853-98-5 204853-99-6
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(psychopharmacol. effects of tianeptine hetero[2,1]benzothiazepine derivs.)
RN 153757-46-1 CAPLUS
CN Thieno[3,4-c][2,1]benzothiazepin-10(5H)-one, 5-methyl-, 4,4-dioxide (CA INDEX NAME)



RN 155144-46-0 CAPLUS
CN 2H-Pyrazolo[3,4-c][2,1]benzothiazepin-4(9H)-one, 9-methyl-, 10,10-dioxide (CA INDEX NAME)



RN 155144-49-3 CAPLUS
CN 2H-Pyrazolo[3,4-c][2,1]benzothiazepin-4(9H)-one, 2,9-dimethyl-, 10,10-dioxide (CA INDEX NAME)



RN 198212-74-7 CAPLUS
CN Thieno[3,4-c][2,1]benzothiazepin-10(5H)-one, 5-methyl-, oxime, 4,4-dioxide (CA INDEX NAME)



RN 198212-80-5 CAPLUS
CN Thieno[3,4-c][2,1]benzothiazepin-10-ol, 5,10-dihydro-5-methyl-, 4,4-dioxide (CA INDEX NAME)



RN 198212-84-9 CAPLUS
CN 2H-Pyrazolo[3,4-c][2,1]benzothiazepin-4-ol, 4,9-dihydro-2,9-dimethyl-, 10,10-dioxide (CA INDEX NAME)



RN 204853-98-5 CAPLUS
CN 2H-Pyrazolo[3,4-c][2,1]benzothiazepin-4(9H)-one, 2,9-dimethyl-, oxime, 10,10-dioxide (CA INDEX NAME)



RN 204853-99-6 CAPLUS
CN 2H-Pyrazolo[3,4-c][2,1]benzothiazepin-4(9H)-one, 9-methyl-, oxime, 10,10-dioxide (CA INDEX NAME)



REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2000:369035 CAPLUS
DOCUMENT NUMBER: 133:135298
TITLE: Synthesis of new thieno- and pyrazolo[2,1]benzothiazepine derivatives with potential antidepressant properties
AUTHOR(S): Vega, S.; Diaz, J. A.; Darias, V.; Mateo, C. C. Sanchez
CORPORATE SOURCE: Instituto de Quimica Medica, CSIC, Madrid, 28006, Spain
SOURCE: Journal of Heterocyclic Chemistry (2000), 37(2), 389-393
CODEN: JHTCAD; ISSN: 0022-152X
PUBLISHER: HeteroCorporation
DOCUMENT TYPE: Journal
LANGUAGE: English
AB In this paper we describe a series of new thieno- and pyrazolo[2,1]benzothiazepine derivs., which were synthesized by two different methods, both starting from tricyclic alcs. Several components of this series were effective p. o. (per os, orally) in different pharmacol. tests currently employed in the evaluation of antidepressant activity.
IT 150832-63-6P 150832-64-7P 253177-78-5P 253177-79-6P 286854-09-9P 286854-10-2P 286854-12-4P 286854-13-5P 286854-20-4P 286854-21-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and antidepressant properties of thieno- and pyrazolobenzothiazepines)
RN 150832-63-6 CAPLUS
CN Ethanamine, 2-[(5,10-dihydro-5-methyl-4,4-dioxidothieno[3,4-c][2,1]benzothiazepin-10-yl)oxy]-N-methyl-, (2Z)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 150555-77-4
CMF C15 H18 N2 O3 S2



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 150832-64-7 CAPLUS
CN Butanedioic acid, compd. with 4,9-dihydro-2,9-dimethyl-4-[2-(1-pyrrolidinyl)ethoxy]-2H-pyrazolo[3,4-c][2,1]benzothiazepine dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 150555-76-3
CMF C18 H24 N4 O3 S



CM 2

CRN 110-15-6
CMF C4 H6 O4



RN 253177-78-5 CAPLUS
CN 2H-Pyrazolo[3,4-c][2,1]benzothiazepine, 4,9-dihydro-2,9-dimethyl-4-[2-(1-piperidinyl)ethoxy]-, 10,10-dioxide (CA INDEX NAME)



RN 253177-79-6 CAPLUS
CN 2H-Pyrazolo[3,4-c][2,1]benzothiazepine, 4,9-dihydro-2,9-dimethyl-4-[2-(1-piperazinyl)ethoxy]-, 10,10-dioxide (CA INDEX NAME)



RN 286854-09-9 CAPLUS
CN Ethanamine, 2-[(5,10-dihydro-5-methyl-4,4-dioxidothieno[3,4-c][2,1]benzothiazepin-10-yl)oxy]-N,N-dimethyl-, (2Z)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 253177-70-7
CMF C16 H20 N2 O3 S2



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 286854-10-2 CAPLUS
CN Thieno[3,4-c][2,1]benzothiazepine,
5,10-dihydro-5-methyl-10-[2-(1-pyrrolidinyl)ethoxy]-, 4,4-dioxide,
(2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 253177-71-8
CMF C18 H22 N2 O3 S2



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 286854-12-4 CAPLUS
CN Thieno[3,4-c][2,1]benzothiazepine,
5,10-dihydro-5-methyl-10-[2-(1-piperidinyl)ethoxy]-, 4,4-dioxide,
(2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 286854-11-3
CMF C19 H24 N2 O3 S2



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 286854-13-5 CAPLUS
CN Thieno[3,4-c][2,1]benzothiazepine,
5,10-dihydro-5-methyl-10-[2-(1-piperazinyl)ethoxy]-, 4,4-dioxide,
(2Z)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 253177-72-9
CMF C18 H23 N3 O3 S2



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 286854-20-4 CAPLUS
CN Ethanamine, 2-[(4,9-dihydro-2,9-dimethyl-10,10-dioxido-2H-pyrazolo[3,4-c][2,1]benzothiazepin-4-yl)oxy]-N-methyl-, (2Z)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 253177-76-3
CMF C15 H20 N4 O3 S



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 286854-21-5 CAPLUS
CN Ethanamine, 2-[(4,9-dihydro-2,9-dimethyl-10,10-dioxido-2H-pyrazolo[3,4-c][2,1]benzothiazepin-4-yl)oxy]-N,N-dimethyl-, (2Z)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 253177-77-4
CMF C16 H22 N4 O3 S



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



IT 198212-80-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation and antidepressant properties of thieno- and pyrazolobenzothiazepines)
RN 198212-80-5 CAPLUS
CN Thieno[3,4-c][2,1]benzothiazepin-10-ol, 5,10-dihydro-5-methyl-, 4,4-dioxide (CA INDEX NAME)



IT 150555-84-3P 198212-84-9P 286854-08-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and antidepressant properties of thieno- and pyrazolobenzothiazepines)
RN 150555-84-3 CAPLUS
CN Thieno[3,4-c][2,1]benzothiazepine, 10-(2-bromoethoxy)-5,10-dihydro-5-methyl-, 4,4-dioxide (CA INDEX NAME)



RN 198212-84-9 CAPLUS
CN 2H-Pyrazolo[3,4-c][2,1]benzothiazepin-4-ol, 4,9-dihydro-2,9-dimethyl-, 10,10-dioxide (CA INDEX NAME)



RN 286854-08-8 CAPLUS
CN 2H-Pyrazolo[3,4-c][2,1]benzothiazepine, 4-(2-bromoethoxy)-4,9-dihydro-2,9-dimethyl-, 10,10-dioxide (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 10 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1999:705433 CAPLUS
DOCUMENT NUMBER: 132:58715
TITLE: New thieno and pyrazolo[2,1]benzothiazepine derivatives with antidepressant activity
AUTHOR(S): Darias, V.; Sanchez-Mateo, C. C.; Exposito-Orta, M. A.; Albertos, L. M.; Diaz, J. A.; Vega, S.
CORPORATE SOURCE: Departamento de Farmacologia, Facultad de Farmacia, Universidad de La Laguna, Spain
SOURCE: Pharmazie (1999), 54(10), 783-784
CODEN: PHARAT; ISSN: 0031-7144
PUBLISHER: Govi-Verlag Pharmazeutischer Verlag
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Several compds. of the hetero[2,1]benzothiazepine series under study were effective orally in different animal models predictive of antidepressant activity, like the Porsolt test and antagonism to tetrabenazine-induced effects. Two thieno derivs., di-Me thieno[3,4-c]benzothiazepine and thieno[3,2-c]benzothiazepine, were in this order the most effective, with activities similar or better than those of reference drugs (imipramine and tianeptine). The pyrazolo[3,4-c] derivs., however, showed a lower degree of activity in these tests.
IT 150555-76-3 150555-77-4 253177-70-7
253177-71-8 253177-72-9 253177-76-3
253177-77-4 253177-78-5 253177-79-6
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(thieno and pyrazolo[2,1]benzothiazepine derivs. with antidepressant activity)
RN 150555-76-3 CAPLUS
CN 2H-Pyrazolo[3,4-c][2,1]benzothiazepine, 4,9-dihydro-2,9-dimethyl-4-[2-(1-pyrrolidinyl)ethoxy]-, 10,10-dioxide (CA INDEX NAME)



RN 150555-77-4 CAPLUS
CN Ethanamine, 2-[(5,10-dihydro-5-methyl-4,4-dioxidothieno[3,4-

c][2,1]benzothiazepin-10-yl)oxy]-N-methyl- (CA INDEX NAME)



RN 253177-70-7 CAPLUS
CN Ethanamine, 2-[(5,10-dihydro-5-methyl-4,4-dioxidothieno[3,4-c][2,1]benzothiazepin-10-yl)oxy]-N,N-dimethyl- (CA INDEX NAME)



RN 253177-71-8 CAPLUS
CN Thieno[3,4-c][2,1]benzothiazepine, 5,10-dihydro-5-methyl-10-[2-(1-pyrrolidinyl)ethoxy]-, 4,4-dioxide (CA INDEX NAME)



RN 253177-72-9 CAPLUS
CN Thieno[3,4-c][2,1]benzothiazepine, 5,10-dihydro-5-methyl-10-[2-(1-piperazinyl)ethoxy]-, 4,4-dioxide (CA INDEX NAME)



RN 253177-76-3 CAPLUS
CN Ethanamine, 2-[(4,9-dihydro-2,9-dimethyl-10,10-dioxido-2H-pyrazolo[3,4-c][2,1]benzothiazepin-4-yl)oxy]-N-methyl- (CA INDEX NAME)



RN 253177-77-4 CAPLUS
CN Ethanamine, 2-[(4,9-dihydro-2,9-dimethyl-10,10-dioxido-2H-pyrazolo[3,4-c][2,1]benzothiazepin-4-yl)oxy]-N,N-dimethyl- (CA INDEX NAME)



RN 253177-78-5 CAPLUS
CN 2H-Pyrazolo[3,4-c][2,1]benzothiazepine, 4,9-dihydro-2,9-dimethyl-4-[2-(1-piperidinyl)ethoxy]-, 10,10-dioxide (CA INDEX NAME)



RN 253177-79-6 CAPLUS
CN 2H-Pyrazolo[3,4-c][2,1]benzothiazepine, 4,9-dihydro-2,9-dimethyl-4-[2-(1-piperazinyl)ethoxy]-, 10,10-dioxide (CA INDEX NAME)



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 11 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1998:116568 CAPLUS
DOCUMENT NUMBER: 128:238994
ORIGINAL REFERENCE NO.: 128:47137a,47140a
TITLE: Antidepressant activity of new hetero[2,1]benzothiazepine derivatives
AUTHOR(S): Vega, S.; Diaz, J. A.; Darias, V.; Sanchez Mateo, C. C.; Albertos, L. M.
CORPORATE SOURCE: Instituto Quimica Medica, Madrid, E-28006, Spain
SOURCE: Pharmazie (1998), 53(2), 130-134
CODEN: PHARAT; ISSN: 0031-7144
PUBLISHER: Govi-Verlag Pharmazeutischer Verlag
DOCUMENT TYPE: Journal
LANGUAGE: English
AB A number of thieno and pyrazolo[2,1]benzothiazepine derivs. as well as several synthetic intermediate compds. were tested for acute toxicity and antidepressant activity in mice. Some of these compds. were effective in the tetrabenazine and Porsolt tests.
IT 153757-46-1
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
(antidepressant activity of new hetero[2,1]benzothiazepine derivs.)
RN 153757-46-1 CAPLUS
CN Thieno[3,4-c][2,1]benzothiazepin-10(5H)-one, 5-methyl-, 4,4-dioxide (CA INDEX NAME)



IT 155144-46-0P 155144-49-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(antidepressant activity of new hetero[2,1]benzothiazepine derivs.)
RN 155144-46-0 CAPLUS
CN 2H-Pyrazolo[3,4-c][2,1]benzothiazepin-4(9H)-one, 9-methyl-, 10,10-dioxide (CA INDEX NAME)



RN 155144-49-3 CAPLUS
CN 2H-Pyrazolo[3,4-c][2,1]benzothiazepin-4(9H)-one, 2,9-dimethyl-, 10,10-dioxide (CA INDEX NAME)



IT 198212-74-7P 198212-80-5P 198212-84-9P
204853-98-5P 204853-99-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(antidepressant activity of new hetero[2,1]benzothiazepine derivs.)
RN 198212-74-7 CAPLUS
CN Thieno[3,4-c][2,1]benzothiazepin-10(5H)-one, 5-methyl-, oxime, 4,4-dioxide (CA INDEX NAME)



RN 198212-80-5 CAPLUS
CN Thieno[3,4-c][2,1]benzothiazepin-10-ol, 5,10-dihydro-5-methyl-, 4,4-dioxide (CA INDEX NAME)



RN 198212-84-9 CAPLUS
CN 2H-Pyrazolo[3,4-c][2,1]benzothiazepin-4-ol, 4,9-dihydro-2,9-dimethyl-, 10,10-dioxide (CA INDEX NAME)



RN 204853-98-5 CAPLUS
CN 2H-Pyrazolo[3,4-c][2,1]benzothiazepin-4(9H)-one, 2,9-dimethyl-, oxime, 10,10-dioxide (CA INDEX NAME)



RN 204853-99-6 CAPLUS
CN 2H-Pyrazolo[3,4-c][2,1]benzothiazepin-4(9H)-one, 9-methyl-, oxime, 10,10-dioxide (CA INDEX NAME)


Me
O
N
S
O
N
NH
N
OH

L9 ANSWER 12 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1997:644488 CAPLUS
DOCUMENT NUMBER: 127:346367
ORIGINAL REFERENCE NO.: 127:67963a,67966a
TITLE: Synthesis of new hetero[2,1]benzothiazepine derivatives
AUTHOR(S): Vega, Salvador; Diaz, Juan A.
CORPORATE SOURCE: Instituto de Quimica Medica, CSIC, Madrid, 28006, Spain
SOURCE: Journal of Heterocyclic Chemistry (1997), 34(4), 1191-1194
CODEN: JHTCAD; ISSN: 0022-152X
PUBLISHER: HeteroCorporation
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB As part of an investigation directed to the search of new neurotropic agents, a number of hydroxy and hydroximino derivs. of the novel thieno and pyrazolo[2,1]benzothiazepine ring systems, e.g., I, were prepared Assignments of the Z and E hydroximino isomers were performed by study of their 1H and 13C NMR spectra and NOE expts.

IT 153757-46-1 155144-46-0 155144-49-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of heterobenzothiazepine derivs.)

RN 153757-46-1 CAPLUS
CN Thieno[3,4-c][2,1]benzothiazepin-10(5H)-one, 5-methyl-, 4,4-dioxide (CA INDEX NAME)



RN 155144-46-0 CAPLUS
CN 2H-Pyrazolo[3,4-c][2,1]benzothiazepin-4(9H)-one, 9-methyl-, 10,10-dioxide (CA INDEX NAME)



RN 155144-49-3 CAPLUS
CN 2H-Pyrazolo[3,4-c][2,1]benzothiazepin-4(9H)-one, 2,9-dimethyl-, 10,10-dioxide (CA INDEX NAME)



IT 150555-86-5P 198212-74-7P 198212-76-9P
198212-77-0P 198212-78-1P 198212-80-5P
198212-84-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of heterobenzothiazepine derivs.)
RN 150555-86-5 CAPLUS
CN 2H-Pyrazolo[3,4-c][2,1]benzothiazepin-4(9H)-one, 2,9-dimethyl-, oxime, 10,10-dioxide, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 198212-74-7 CAPLUS
CN Thieno[3,4-c][2,1]benzothiazepin-10(5H)-one, 5-methyl-, oxime, 4,4-dioxide (CA INDEX NAME)



RN 198212-76-9 CAPLUS
CN 2H-Pyrazolo[3,4-c][2,1]benzothiazepin-4(9H)-one, 2,9-dimethyl-, oxime, 10,10-dioxide, (4E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 198212-77-0 CAPLUS
CN 2H-Pyrazolo[3,4-c][2,1]benzothiazepin-4(9H)-one, 9-methyl-, oxime, 10,10-dioxide, (4E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 198212-78-1 CAPLUS
CN 2H-Pyrazolo[3,4-c][2,1]benzothiazepin-4(9H)-one, 9-methyl-, oxime, 10,10-dioxide, (4Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 198212-80-5 CAPLUS
CN Thieno[3,4-c][2,1]benzothiazepin-10-ol, 5,10-dihydro-5-methyl-, 4,4-dioxide (CA INDEX NAME)



RN 198212-84-9 CAPLUS
CN 2H-Pyrazolo[3,4-c][2,1]benzothiazepin-4-ol, 4,9-dihydro-2,9-dimethyl-, 10,10-dioxide (CA INDEX NAME)



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 13 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1996:495431 CAPLUS
DOCUMENT NUMBER: 125:184907
ORIGINAL REFERENCE NO.: 125:34303a,34306a
TITLE: Synthesis and antidepressant evaluation of new hetero[2,1]benzothiazepine derivatives
AUTHOR(S): Diaz, Juan A.; Vega, Salvador; Exposito, Maria A.; Sanchez Mateo, Candelaria C.; Darias, Victoriano
CORPORATE SOURCE: Inst. Quimica Medica, CSIC, Madrid, 28006, Spain
SOURCE: Archiv der Pharmazie (Weinheim, Germany) (1996), 329(7), 352-360
CODEN: ARPMAS; ISSN: 0365-6233
PUBLISHER: VCH
DOCUMENT TYPE: Journal
LANGUAGE: English
AB As a part of a research program directed to the discovery of novel antidepressant agents, a series of new hetero[2,1]benzothiazepine derivs. was synthesized. Some of these compds. antagonized the ptosis and motor depression induced by tetrabenazine and were also active in the Porsolt forced swimming test. These activities, however, were lower than those elicited by the reference drugs viloxazine and tianeptine. Structure activity relations are discussed.
IT 181145-37-9P 181145-38-0P 181145-39-1P
181145-40-4P 181145-46-0P 181145-48-2P
181145-50-6P 181145-52-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(synthesis and antidepressant evaluation of new hetero[2,1]benzothiazepine derivs.)
RN 181145-37-9 CAPLUS
CN Thieno[3,4-c][2,1]benzothiazepin-10(5H)-one, 5-methyl-, O-[2-(dimethylamino)ethyl]oxime, 4,4-dioxide, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 181145-38-0 CAPLUS
CN Thieno[3,4-c][2,1]benzothiazepin-10(5H)-one, 5-methyl-, O-[2-(1-pyrrolidinyl)ethyl]oxime, 4,4-dioxide, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 181145-39-1 CAPLUS
CN Thieno[3,4-c][2,1]benzothiazepin-10(5H)-one, 5-methyl-, O-[2-(1-piperidinyl)ethyl]oxime, 4,4-dioxide, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 181145-40-4 CAPLUS
CN Thieno[3,4-c][2,1]benzothiazepin-10(5H)-one, 5-methyl-, O-[2-(4-morpholinyl)ethyl]oxime, 4,4-dioxide, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 181145-46-0 CAPLUS
CN 2H-Pyrazolo[3,4-c][2,1]benzothiazepin-4(9H)-one, 2,9-dimethyl-, O-[2-(dimethylamino)ethyl]oxime, 10,10-dioxide, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 181145-45-9
CMF C16 H21 N5 O3 S



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 181145-48-2 CAPLUS
CN 2H-Pyrazolo[3,4-c][2,1]benzothiazepin-4(9H)-one, 2,9-dimethyl-, O-[2-(1-pyrrolidinyl)ethyl]oxime, 10,10-dioxide, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 181145-47-1
CMF C18 H23 N5 O3 S



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 181145-50-6 CAPLUS
CN 2H-Pyrazolo[3,4-c][2,1]benzothiazepin-4(9H)-one, 2,9-dimethyl-, O-[2-(1-piperidinyl)ethyl]oxime, 10,10-dioxide, (2Z)-2-butenedioate (1:1)

(9CI) (CA INDEX NAME)

CM 1

CRN 181145-49-3
CMF C19 H25 N5 O3 S



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 181145-52-8 CAPLUS
CN 2H-Pyrazolo[3,4-c][2,1]benzothiazepin-4(9H)-one, 2,9-dimethyl-, O-[2-(4-morpholinyl)ethyl]oxime, 10,10-dioxide, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 181145-51-7
CMF C18 H23 N5 O4 S



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



L9 ANSWER 14 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1996:187571 CAPLUS
DOCUMENT NUMBER: 124:317117
ORIGINAL REFERENCE NO.: 124:58813a
TITLE: Preparation and regiochemical assignments of new pyrazolo[3,4-c][2,1]benzothiazepines
AUTHOR(S): Arranz, Ester; Diaz, Juan A.; Morante, Esther; Perez, Carmen; Vega, Salvador
CORPORATE SOURCE: Instituto de Quimica Medica, CSIC, Madrid, 28006, Spain
SOURCE: Journal of Heterocyclic Chemistry (1996), 33(1), 151-6
CODEN: JHTCAD; ISSN: 0022-152X
PUBLISHER: HeteroCorporation
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I



II

AB The preparation of new pyrazolo[3,4-c][2,1]benzothiazepines I (R = Me, Et, CH2Ph, etc.) and II (R = Me, Et, CH2Ph) substituted at the nitrogen atoms of the pyrazole moiety is described. It was carried out by reaction of the 4,9-dihydro-9-methyl-4,10,10-trioxo-1(2)H-pyrazolo[3,4-c][2,1]benzothiazepine with several alkylating agents under both classical and phase-transfer catalysis (PTC) conditions. Assignments of the N-alkyl regioisomers obtained were performed by study of their 1H NMR spectra and NOE expts.
IT 155144-46-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation and regiochem. of pyrazolobenzothiazepines)
RN 155144-46-0 CAPLUS
CN 2H-Pyrazolo[3,4-c][2,1]benzothiazepin-4(9H)-one, 9-methyl-, 10,10-dioxide (CA INDEX NAME)



IT 155144-49-3P 176383-35-0P 176383-36-1P
176383-37-2P 176383-38-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and regiochem. of pyrazolobenzothiazepines)
RN 155144-49-3 CAPLUS
CN 2H-Pyrazolo[3,4-c][2,1]benzothiazepin-4(9H)-one, 2,9-dimethyl-,
10,10-dioxide (CA INDEX NAME)



RN 176383-35-0 CAPLUS
CN 2H-Pyrazolo[3,4-c][2,1]benzothiazepin-4(9H)-one, 2-ethyl-9-methyl-,
10,10-dioxide (CA INDEX NAME)



RN 176383-36-1 CAPLUS
CN 2H-Pyrazolo[3,4-c][2,1]benzothiazepin-4(9H)-one,
9-methyl-2-(phenylmethyl)-, 10,10-dioxide (CA INDEX NAME)



RN 176383-37-2 CAPLUS
CN 2H-Pyrazolo[3,4-c][2,1]benzothiazepin-4(9H)-one,

9-methyl-2-(2-phenylethyl)-, 10,10-dioxide (CA INDEX NAME)



RN 176383-38-3 CAPLUS
CN 2H-Pyrazolo[3,4-c][2,1]benzothiazepin-4(9H)-one, 2-cyclohexyl-9-methyl-, 10,10-dioxide (CA INDEX NAME)



L9 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1994:409363 CAPLUS
DOCUMENT NUMBER: 121:9363
ORIGINAL REFERENCE NO.: 121:1981a,1984a
TITLE: Synthesis of 1H- and 2H-pyrazolo[3,4-c][2,1]benzothiazepines
AUTHOR(S): Diaz, Juan A.; Vega, Salvador
CORPORATE SOURCE: Inst. Quim. Med., CSIC, Madrid, 28006, Spain
SOURCE: Journal of Heterocyclic Chemistry (1994), 31(1), 93-6
CODEN: JHTCAD; ISSN: 0022-152X
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I



II

AB Starting from Et chlorosulfonylpyrazole-4-carboxylates the authors have carried out the synthesis of ketones I and II which are the first two structures of the novel 1H- and 2H-pyrazolo[3,4-c][2,1]benzothiazepine ring systems.

IT 155144-49-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 155144-49-3 CAPLUS
CN 2H-Pyrazolo[3,4-c][2,1]benzothiazepin-4(9H)-one, 2,9-dimethyl-, 10,10-dioxide (CA INDEX NAME)



L9 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1994:323617 CAPLUS
DOCUMENT NUMBER: 120:323617
ORIGINAL REFERENCE NO.: 120:56945a,56948a
TITLE: Process for preparation of trioxopyrazolo[2,1]benzothiazepines as potential therapeutics
INVENTOR(S): Vega Noverola, Salvador; Diaz Martin, Juan Antonio
PATENT ASSIGNEE(S): Consejo Superior de Investigaciones Cientificas, Spain
SOURCE: Span., 5 pp.
CODEN: SPXXAD
DOCUMENT TYPE: Patent
LANGUAGE: Spanish
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
ES 2046941	A1	19940201	ES 1991-2366	19911024
ES 2046941	B1	19940816		
PRIORITY APPLN. INFO.:			ES 1991-2366	19911024

OTHER SOURCE(S): CASREACT 120:323617; MARPAT 120:323617
GI



I



II

AB Title compds. and analogs I [R1 = H, (un)substituted alkyl or arylalkyl; R2 = H, halo, NO2, amino, sulfonamido, CF3; X = N, NMe, NH, CH; Y = N, NMe, NH, CH, CMe; Z = N, CH, CMe] are prepared by a claimed 3-step process, illustrated below. I are useful as intermediates, or potentially as antibacterial agents, diuretics, or antihypertensives. Sulfonamidation of Et 3(5)-(chlorosulfonyl)pyrazole-4-carboxylate with PhNHMe in refluxing THF gave sulfonamide II (R = Et), which was hydrolyzed by refluxing 1N KOH to give the corresponding acid II (R = H). Cyclization of the acid by polyphosphoric acid in boiling xylene gave I (R1 = Me, R2 = H, X = N, Y = NH, Z = CH).
IT 155144-46-0P 155144-49-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as intermediate or potential therapeutic)
RN 155144-46-0 CAPLUS
CN 2H-Pyrazolo[3,4-c][2,1]benzothiazepin-4(9H)-one, 9-methyl-, 10,10-dioxide (CA INDEX NAME)



RN 155144-49-3 CAPLUS
CN 2H-Pyrazolo[3,4-c][2,1]benzothiazepin-4(9H)-one, 2,9-dimethyl-, 10,10-dioxide (CA INDEX NAME)



L9 ANSWER 17 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1994:217612 CAPLUS
DOCUMENT NUMBER: 120:217612
ORIGINAL REFERENCE NO.: 120:38645a,38648a
TITLE: Synthesis of thieno[3,4-c] and thieno[3,2-c][2,1]benzothiazepines
AUTHOR(S): Vega, Salvador; Diaz, Juan A.
CORPORATE SOURCE: Inst. Quim. Med., CSIC, Madrid, 28006, Spain
SOURCE: Journal of Heterocyclic Chemistry (1993), 30(6), 1509-12
CODEN: JHTCAD; ISSN: 0022-152X
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB Starting from [4,3-c] and [3,2-c] Me (chlorosulfonyl)thiophenecarboxylates the synthesis of ketones I (X = S, Y = CH; X = CH, Y = S) is described. These compds. are the first two representatives of the new thieno[3,4-c] and thieno[3,2-c]benzothiazepine ring systems. The formation of Me 3-chlorosulfonylthiophene-2-carboxylate is also revised.

IT 153757-46-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 153757-46-1 CAPLUS

CN Thieno[3,4-c][2,1]benzothiazepin-10(5H)-one, 5-methyl-, 4,4-dioxide (CA INDEX NAME)



L9 ANSWER 18 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1993:649978 CAPLUS
DOCUMENT NUMBER: 119:249978
ORIGINAL REFERENCE NO.: 119:44605a,44608a
TITLE: Preparation of pharmacologically active tricyclic benzotriazepine derivatives
INVENTOR(S): Vega Noverola, Salvador; Diaz Martin, Juan Antonio
PATENT ASSIGNEE(S): (Csie and Adir et Cie), Spain; Adir et Cie
SOURCE: Eur. Pat. Appl., 25 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 547705	A1	19930623	EP 1992-203913	19921215
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
ES 2040629	A1	19931016	ES 1991-2818	19911218
ES 2040629	B1	19940616		
CA 2085705	A1	19930619	CA 1992-2085705	19921217
ZA 9209777	A	19930623	ZA 1992-9777	19921217
AU 9230303	A	19930624	AU 1992-30303	19921218
JP 06001794	A	19940111	JP 1992-338491	19921218

PRIORITY APPLN. INFO.: ES 1991-2818 A 19911218
OTHER SOURCE(S): MARPAT 119:249978
GI



I

AB Title compds. I [X = N, S, HN, alkyl-N, alkylaryl-N, HC; Y = N, S, HN, alkyl-N, alkylaryl-N, HC; Z = N, S, HC, alkyl-C, aryl-C; R1 = H, alkyl (substituted) arylalkyl; R2 = lH, halo, O2N, (substituted) amine, NC, SO2NH, F3C, C1-36 alkyl, C1-36 alkoxy; R3, R4 = H, halo, HO, alkoxy, HS, (substituted) amino, Het-(C1-5 alkyl)-T wherein T = O, N, S, n = 0, 1, Het = (substituted) heterocyclyl], are prepared NaBH4 was added to 5,10-dihydro-5-methyl-4,4,10-trioxothieno[3,2-c][2,1]-benzothiazopine in MeOH to give I (X = Y = HC, Z = S, R1 = Me, R2 = R4 = H, R3 = HO) which at 100 mg/kg, p.o., showed inhibition of pain in the Siegmund test.
IT 150555-76-3P 150555-77-4P 150555-79-6P
150555-81-0P 150555-88-7P 150832-63-6P
150832-64-7P 150832-65-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as drug)
RN 150555-76-3 CAPLUS

CN 2H-Pyrazolo[3,4-c][2,1]benzothiazepine, 4,9-dihydro-2,9-dimethyl-4-[2-(1-pyrrolidinyl)ethoxy]-, 10,10-dioxide (CA INDEX NAME)



RN 150555-77-4 CAPLUS
CN Ethanamine, 2-[(5,10-dihydro-5-methyl-4,4-dioxidothieno[3,4-c][2,1]benzothiazepin-10-yl)oxy]-N-methyl- (CA INDEX NAME)



RN 150555-79-6 CAPLUS
CN 2H-Pyrazolo[3,4-c][2,1]benzothiazepin-4(9H)-one, 2,9-dimethyl-, O-[2-(dimethylamino)ethyl]oxime, 10,10-dioxide, (4Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 150555-81-0 CAPLUS
CN 1-Propanamine, N,N-dimethyl-3-(5-methyl-4,4-dioxidothieno[3,4-c][2,1]benzothiazepin-10(5H)-ylidene)-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 150555-88-7 CAPLUS
CN 1-Propanamine, N,N-dimethyl-3-(5-methyl-4,4-dioxidothieno[3,4-c][2,1]benzothiazepin-10(5H)-ylidene)-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 150832-63-6 CAPLUS
CN Ethanamine, 2-[(5,10-dihydro-5-methyl-4,4-dioxidothieno[3,4-c][2,1]benzothiazepin-10-yl)oxy]-N-methyl-, (2Z)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 150555-77-4
CMF C15 H18 N2 O3 S2



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 150832-64-7 CAPLUS
CN Butanedioic acid, compd. with 4,9-dihydro-2,9-dimethyl-4-[2-(1-pyrrolidinyl)ethoxy]-2H-pyrazolo[3,4-c][2,1]benzothiazepine dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 150555-76-3
CMF C18 H24 N4 O3 S



CM 2

CRN 110-15-6
CMF C4 H6 O4



RN 150832-65-8 CAPLUS
CN 2H-Pyrazolo[3,4-c][2,1]benzothiazepin-4(9H)-one, 2,9-dimethyl-, O-[2-(dimethylamino)ethyl]oxime, 10,10-dioxide, (4Z)-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 150555-79-6
CMF C16 H21 N5 O3 S

Double bond geometry as shown.



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



IT 150555-84-3 150555-86-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, in preparation of drugs)
RN 150555-84-3 CAPLUS
CN Thieno[3,4-c][2,1]benzothiazepine,
10-(2-bromoethoxy)-5,10-dihydro-5-methyl-, 4,4-dioxide (CA INDEX NAME)



RN 150555-86-5 CAPLUS
CN 2H-Pyrazolo[3,4-c][2,1]benzothiazepin-4(9H)-one, 2,9-dimethyl-, oxime,
10,10-dioxide, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L9 ANSWER 19 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1992:214543 CAPLUS
DOCUMENT NUMBER: 116:214543
ORIGINAL REFERENCE NO.: 116:36365a,36368a
TITLE: Preparation of new trioxothienobenzothiazepines
INVENTOR(S): Vega Noverola, Salvador; Diaz Martin, Juan Antonio
PATENT ASSIGNEE(S): Consejo Superior de Investigaciones Cientificas, Spain
SOURCE: Span., 4 pp.
CODEN: SPXXAD
DOCUMENT TYPE: Patent
LANGUAGE: Spanish
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
ES 2021548	A6	19911101	ES 1990-1576	19900607

PRIORITY APPLN. INFO.: ES 1990-1576 19900607
OTHER SOURCE(S): MARPAT 116:214543
GI



I II

AB Title heterocycles I [R1 = H, alkyl, (un)substituted aralkyl; R2 = H, halo, NO2, amino, sulfonamido, CF3; X = S, CH, CMe, CPh; Y = S, CH, CMe] are prepared in 3 steps: (1) reaction of corresponding sulfonyl chlorides and anilines in the presence of a base to give sulfonamides II (R = undefined esterifying group); (2) alkaline hydrolysis of the esters to give acids II (R = H); and (3) intramol. cyclization of the acids in the presence of a dehydrating agent. I are useful as psychotropics, antibacterials, diuretics, antihypertensives, etc. (no data). For example, PhNHMe and 3-(chlorosulfonyl)-2-(methoxycarbonyl)thiophene reacted in THF to give II (R = R1 = Me, R2 = H, X = CH, Y = S), which was hydrolyzed to II (R = H, others as above) in refluxing 1N KOH. Cyclization by polyphosphoric acid in refluxing PhMe gave I (R1 = Me, R2 = H, X = CH, Y = S). The isomeric I (R1 = Me, R2 = H, X = S, Y = CH) was prepared identically.
IT 140947-43-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as potential drug)
RN 140947-43-9 CAPLUS
CN Thieno[3,4-c][2,1]benzothiazepin-10(5H)-one, 5-methyl- (CA INDEX NAME)


Me
N
S
S
O

L7 ANSWER 144 OF 144 REGISTRY COPYRIGHT 2008 ACS on STN
RN 181145-45-9 REGISTRY
ED Entered STN: 24 Sep 1996
CN 2H-Pyrazolo[3,4-c][2,1]benzothiazepin-4(9H)-one, 2,9-dimethyl-, O-[2-(dimethylamino)ethyl]oxime, 10,10-dioxide (CA INDEX NAME)
MF C16 H21 N5 O3 S
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 139 OF 144 REGISTRY COPYRIGHT 2008 ACS on STN
RN 751459-97-9 REGISTRY
ED Entered STN: 26 Sep 2004
CN Thieno[3,4-c][2,1]benzothiazepin-10(5H)-one, 5-methyl-, O-[2-(1-piperidinyl)ethyl]oxime 4,4-dioxide (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Thieno[3,4-c][2,1]benzothiazepin-10(5H)-one, 5-methyl-, O-[2-(1-piperidinyl)ethyl]oxime, 4,4-dioxide (9CI)
MF C19 H23 N3 O3 S2
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 140 OF 144 REGISTRY COPYRIGHT 2008 ACS on STN
RN 733721-49-8 REGISTRY
ED Entered STN: 27 Aug 2004
CN Thieno[3,4-c][2,1]benzothiazepin-10(5H)-one, 5-methyl-, O-[2-(1-pyrrolidinyl)ethyl]oxime 4,4-dioxide (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Thieno[3,4-c][2,1]benzothiazepin-10(5H)-one, 5-methyl-, O-[2-(1-pyrrolidinyl)ethyl]oxime, 4,4-dioxide (9CI)
MF C18 H21 N3 O3 S2
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 141 OF 144 REGISTRY COPYRIGHT 2008 ACS on STN
RN 181145-51-7 REGISTRY
ED Entered STN: 24 Sep 1996
CN 2H-Pyrazolo[3,4-c][2,1]benzothiazepin-4(9H)-one, 2,9-dimethyl-, O-[2-(4-morpholinyl)ethyl]oxime, 10,10-dioxide (CA INDEX NAME)
MF C18 H23 N5 O4 S
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 142 OF 144 REGISTRY COPYRIGHT 2008 ACS on STN
RN 181145-49-3 REGISTRY
ED Entered STN: 24 Sep 1996
CN 2H-Pyrazolo[3,4-c][2,1]benzothiazepin-4(9H)-one, 2,9-dimethyl-, O-[2-(1-piperidinyl)ethyl]oxime, 10,10-dioxide (CA INDEX NAME)
MF C19 H25 N5 O3 S
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 143 OF 144 REGISTRY COPYRIGHT 2008 ACS on STN
RN 181145-47-1 REGISTRY
ED Entered STN: 24 Sep 1996
CN 2H-Pyrazolo[3,4-c][2,1]benzothiazepin-4(9H)-one, 2,9-dimethyl-, O-[2-(1-pyrrolidinyl)ethyl]oxime, 10,10-dioxide (CA INDEX NAME)
MF C18 H23 N5 O3 S
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 135 OF 144 REGISTRY COPYRIGHT 2008 ACS on STN
RN 790252-11-8 REGISTRY
ED Entered STN: 29 Nov 2004
CN 1H-Pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxamide, N-[(1S,2R)-3-(cyclohexylamino)-2-hydroxy-1-(phenylmethyl)propyl]-7-ethyl-3,4-dihydro-1,3-dimethyl-, 2,2-dioxide (CA INDEX NAME)
FS STEREOSEARCH
MF C31 H42 N4 O4 S
CI COM
SR CA

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 136 OF 144 REGISTRY COPYRIGHT 2008 ACS on STN
RN 790252-07-2 REGISTRY
ED Entered STN: 29 Nov 2004
CN 1H-Pyrrolo[1,2,3-ef]-2,1,5-benzothiadiazepine-9-carboxamide, 7-ethyl-3,4-dihydro-N-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[[[3-(trifluoromethyl)phenyl]methyl]amino]propyl]-1,3-dimethyl-, 2,2-dioxide (CA INDEX NAME)
FS STEREOSEARCH
MF C33 H37 F3 N4 O4 S
CI COM
SR CA

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 137 OF 144 REGISTRY COPYRIGHT 2008 ACS on STN
RN 784118-55-4 REGISTRY
ED Entered STN: 19 Nov 2004
CN Thieno[3,4-c][2,1]benzothiazepin-10(5H)-one, 5-methyl-, O-[2-(4-morpholinyl)ethyl]oxime 4,4-dioxide (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Thieno[3,4-c][2,1]benzothiazepin-10(5H)-one, 5-methyl-, O-[2-(4-morpholinyl)ethyl]oxime, 4,4-dioxide (9CI)
MF C18 H21 N3 O4 S2
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 138 OF 144 REGISTRY COPYRIGHT 2008 ACS on STN
RN 760924-40-1 REGISTRY
ED Entered STN: 11 Oct 2004
CN Thieno[3,4-c][2,1]benzothiazepin-10(5H)-one, 5-methyl-, O-[2-(dimethylamino)ethyl]oxime 4,4-dioxide (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Thieno[3,4-c][2,1]benzothiazepin-10(5H)-one, 5-methyl-, O-[2-(dimethylamino)ethyl]oxime, 4,4-dioxide (9CI)
MF C16 H19 N3 O3 S2
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT